EP0780116A1 - External skin preparation - Google Patents
External skin preparation Download PDFInfo
- Publication number
- EP0780116A1 EP0780116A1 EP96923068A EP96923068A EP0780116A1 EP 0780116 A1 EP0780116 A1 EP 0780116A1 EP 96923068 A EP96923068 A EP 96923068A EP 96923068 A EP96923068 A EP 96923068A EP 0780116 A1 EP0780116 A1 EP 0780116A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- skin
- external preparation
- weight
- quaternary ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 118
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 132
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 94
- 206010013786 Dry skin Diseases 0.000 claims abstract description 71
- 230000006872 improvement Effects 0.000 claims abstract description 70
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 70
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 66
- 230000000694 effects Effects 0.000 claims abstract description 65
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 58
- 229940046009 vitamin E Drugs 0.000 claims abstract description 58
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 58
- 239000011709 vitamin E Substances 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims abstract description 47
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 17
- 239000003623 enhancer Substances 0.000 claims abstract description 6
- 238000013329 compounding Methods 0.000 claims description 129
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 20
- 229940042585 tocopherol acetate Drugs 0.000 claims description 16
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 14
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 14
- 150000004370 vitamin A ester derivatives Chemical class 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 143
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- 239000006210 lotion Substances 0.000 description 67
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 63
- -1 e.g. Substances 0.000 description 47
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 42
- 239000000203 mixture Substances 0.000 description 41
- 238000012360 testing method Methods 0.000 description 39
- 235000019441 ethanol Nutrition 0.000 description 38
- 239000004615 ingredient Substances 0.000 description 36
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 31
- 239000008213 purified water Substances 0.000 description 31
- 239000000284 extract Substances 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 29
- 238000009472 formulation Methods 0.000 description 24
- 239000000499 gel Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 21
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 19
- 230000003631 expected effect Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 16
- 239000004599 antimicrobial Substances 0.000 description 16
- 229940108325 retinyl palmitate Drugs 0.000 description 16
- 235000019172 retinyl palmitate Nutrition 0.000 description 16
- 239000011769 retinyl palmitate Substances 0.000 description 16
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 15
- 229960000984 tocofersolan Drugs 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 14
- 239000003906 humectant Substances 0.000 description 14
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 13
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 230000002633 protecting effect Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 10
- 229960002216 methylparaben Drugs 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000004166 Lanolin Substances 0.000 description 8
- 235000019388 lanolin Nutrition 0.000 description 8
- 229940039717 lanolin Drugs 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- 239000004264 Petrolatum Substances 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 239000006096 absorbing agent Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 229920000609 methyl cellulose Polymers 0.000 description 7
- 235000010981 methylcellulose Nutrition 0.000 description 7
- 239000001923 methylcellulose Substances 0.000 description 7
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 7
- 229940066842 petrolatum Drugs 0.000 description 7
- 235000019271 petrolatum Nutrition 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 229940032094 squalane Drugs 0.000 description 7
- JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940057995 liquid paraffin Drugs 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 230000004526 pharmaceutical effect Effects 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 229960000342 retinol acetate Drugs 0.000 description 5
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 5
- 235000019173 retinyl acetate Nutrition 0.000 description 5
- 239000011770 retinyl acetate Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 4
- 229940055577 oleyl alcohol Drugs 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- 235000017788 Cydonia oblonga Nutrition 0.000 description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 244000302544 Luffa aegyptiaca Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000004164 Wax ester Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 235000019983 sodium metaphosphate Nutrition 0.000 description 2
- WRZYGPIFICWRCG-OOFFSTKBSA-M sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trih Chemical compound [Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WRZYGPIFICWRCG-OOFFSTKBSA-M 0.000 description 2
- 235000002316 solid fats Nutrition 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 235000019386 wax ester Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- DJCYDDALXPHSHR-UHFFFAOYSA-N 2-(2-propoxyethoxy)ethanol Chemical compound CCCOCCOCCO DJCYDDALXPHSHR-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-M 3,4,5-trimethoxycinnamate Chemical compound COC1=CC(C=CC([O-])=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-M 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RDBLNMQDEWOUIB-UHFFFAOYSA-N 5-methyl-2-phenyl-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1C1=CC=CC=C1 RDBLNMQDEWOUIB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000209485 Nuphar Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 235000005247 Rumex japonicus Nutrition 0.000 description 1
- 244000189123 Rumex japonicus Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241001622901 Scomberomorus commerson Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000005158 Thymus praecox ssp. arcticus Nutrition 0.000 description 1
- 235000004054 Thymus serpyllum Nutrition 0.000 description 1
- 240000006001 Thymus serpyllum Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- UDRYFKCHZFVZGJ-UHFFFAOYSA-N [5-hexadecanoyloxy-4-(hexadecanoyloxymethyl)-6-methylpyridin-3-yl]methyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C)C(OC(=O)CCCCCCCCCCCCCCC)=C1COC(=O)CCCCCCCCCCCCCCC UDRYFKCHZFVZGJ-UHFFFAOYSA-N 0.000 description 1
- NRTJGTSOTDBPDE-UHFFFAOYSA-N [dimethyl(methylsilyloxy)silyl]oxy-dimethyl-trimethylsilyloxysilane Chemical compound C[SiH2]O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C NRTJGTSOTDBPDE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- KQZNFGJQTPAURD-NBWQQBAWSA-N ascorbyl dipalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(O)=C1O KQZNFGJQTPAURD-NBWQQBAWSA-N 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000012179 bayberry wax Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012174 chinese wax Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CXPOFJRHCFPDRI-UHFFFAOYSA-N dodecylbenzene;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1 CXPOFJRHCFPDRI-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000012182 japan wax Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099576 lamium album extract Drugs 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000000457 mentha pulegium l. herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/002—Aftershave preparations
Definitions
- the present invention relates to an external preparation for skin and in particular, relates to an enhancer of betaine which has a moisturizing function and a skin improvement function.
- a maintenance function of a beautiful skin state is one of the fundamental functions of an external preparation for skin such as cosmetics. In order to maintain this beautiful skin state, it is essential to condition the sulci cutis and cristae of the skin by preventing or improving a skin roughness.
- humectants such as glycerin, sorbitol, propylene glycol, polysaccharide, and the like have been compounded into cosmetics.
- humectants e.g., polysaccharide may cause precipitation in the formulation which contains a large amounts of alcohol.
- a cosmetic which is compounded with trimethylglycine independently can reduce the sticky feel of use.
- trimethylglycine is compounded in the dosage which is enough to exhibit the improvement effect of the skin state that trimethylglycine is possessed
- an external preparation for skin has a tendency to be attended with "powdery feel of use" by the presence of trimethylglycine. Therefore, the external preparation for skin which is compounded trimethylglycine independently, does not sufficiently satisfy the requirements of users.
- the object of the present invention is to provide an external preparation for skin which can sufficiently exhibit the moisturizing function and the skin improvement function of trimethylglycine.
- the present invention provides an external preparation for skin comprising a quaternary ammonium salt which is shown by following constitutional formula (I), and, an enhancer of the moisturizing function, and the skin improvement function of a quaternary ammonium salt selected from the group consisting of vitamin E types, vitamin A derivatives, and alkyl denatured carboxyvinyl polymer.
- a quaternary ammonium salt selected from the group consisting of vitamin E types, vitamin A derivatives, and alkyl denatured carboxyvinyl polymer.
- R 1 , R 2 , and R 3 show alkyl groups having a carbon number from 1 to 6. A sum total of the carbon number of R 1 , R 2 , R 3 , and n is 8 or less.
- Each carbon number of R 1 , R 2 , and R 3 can be same or different.
- the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 30% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- vitamin E types are tocopherol and/or vitamin E acetate.
- the compounding amount of the vitamin E types is in the range from 0.0001% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the vitamin E types is in the range from 0.001% by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- vitamin A derivatives are vitamin A ester.
- the compounding amount of the vitamin A derivatives is in the range from 1 ⁇ 10 -5 % by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the vitamin A derivatives is in the range from 1 ⁇ 10 -4 % by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the alkyl denatured carboxyvinyl polymer is in the range from 0.01% by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the alkyl denatured carboxyvinyl polymer is in the range from 0.05% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
- a quaternary ammonium salt which is shown in constitutional formula (I) and compounded with the external preparation for skin of the present invention is a mode of the molecule which is generally called "betaine".
- R 1 , R 2 , and R 3 show alkyl groups having a carbon number from 1 to 6. And also, a sum total of the carbon number of R 1 , R 2 , R 3 , and n (which is integer 0 or more) is 8 or less.
- the straight chain alkyl group or branched chain alkyl group of said carbon number can be widely applied. Namely, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, an isohexyl group, a 3-methylpentyl group, a 2,2-dimethylbutyl group, a 2,3-dimethylbutyl group, and the like can be exemplified as the alkyl group which has said carbon number.
- R 1 , R 2 , and R 3 can be same or different.
- the combination of the alkyl groups in the tendency to reduce the property of the quaternary ammonium salt as an amphoteric surfactant as much as possible, it is preferable to decrease the carbon number of R 1 , R 2 , and R 3 as little as possible. Therefore, it is preferable in the case where the combination of all alkyl groups of the quaternary ammonium salt (I) are methyl groups at the same time, and n is 0, namely, it is more preferable to compound trimethylglycine or ⁇ -butyrobetaine (that all alkyl groups are methyl groups at the same time and n is 2) as a quaternary ammonium salt. And also, trimethylglycine and ⁇ -butyrobetaine are known to be widely distributed in the animal and vegetable kingdoms, and they are the preferable quaternary ammonium salt for planning a physiologically beautiful skin state as much as possible.
- vitamin E types which can synergistically enhance the moisturizing function and the skin improvement function of the quaternary ammonium salt by combining it with the quaternary ammonium salt.
- vitamin E types which can be compounded for the external preparation of the present invention are selected from vitamin E such as natural vitamin E, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol; vitamin E derivatives such as vitamin E acetate, vitamin E nicotinate, ⁇ -tocopherol-2, L- ascorbic acid phosphate diester; the salt of these, and the like.
- vitamin E types listed here are comprised of, needless to say d-isomer which ordinarily exists in nature, and optical isomers that can be synthesized such as l-isomer, or dl-isomer which is the mixture of d-isomer and l-isomer. In the case where we are referring to vitamin E types in the present invention, unless otherwise stated, it comprises all these possibilities.
- the external preparation has a formulation form which is desired to be transparent (e.g., water solution type or solubilization type)
- the vitamin E types listed here can be synthesized by the publicly known methods (e.g., Trost method) and can also use vitamin E purchased in the market.
- the compounding amount of the above- mentioned quaternary ammonium salt (I) is preferably in the range from 0.01% by weight to 30% by weight, and more preferably in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the above- mentioned quaternary ammonium salt (I) is preferably in the range from 0.01% by weight to 30% by weight, and more preferably in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- the compounding amount of the above- mentioned quaternary ammonium salt (I) is preferably in the range from 0.01% by weight to 30% by weight, and more preferably in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- the moisturizing function and the skin improvement function of the quaternary ammonium salt becomes insufficient, and it cannot sufficiently control the stickiness which is caused by the addition of other humectants.
- the effective increase which corresponds to the increase of the compounding amount cannot be expected.
- the feel of use of external preparation for skin which is compounded with such an excessive amount of the quaternary ammonium salt (I) is powdery and is not preferable because of the deteriorating of suitability for skin.
- the quaternary ammonium salt (I) is compounded in the range from 0.01% by weight to 1% by weight with respect to the whole amount of the external preparation for skin, it generally exhibits the moisturizing function and skin improvement function of the quaternary ammonium salt (I). However, it sometimes cannot sufficiently control the sticky feel of use, according to the property of other humectants with which it coexists.
- the quaternary ammonium salt (I) is compounded in the range from 20% by weight to 30% by weight with respect to the whole amount of the external preparation for skin in accordance with the present invention, a specific powdery feel of use is possible by compounding of this quaternary ammonium salt (I), according to the formulation form.
- the compounding amount of the vitamin E types which are compounded to the external preparation for skin in accordance with the present invention is in the range from 0.0001% by weight to 2.0% by weight with respect to the whole amount of the external preparation for skin (hereinafter, when this application refers to as "preferable compounding range", as shown in here, it means the preferable compounding range of the compounding ingredients for the external preparation for skin of the present invention).
- the compounding amount of the vitamin E types is in the range from 0.001% by weight to 0.5% by weight with respect to the whole amount of the external preparation for skin (hereinafter, when this application refers to as "optimum compounding range", as shown in here, it means the more preferable compounding range of the compounding ingredients of the external preparation for skin in accordance with the present invention).
- the compounding amount of the vitamin E types is less than 0.0001% by weight, it is not preferable because the enhancement actions of moisturizing function, skin roughness improvement function, and skin roughness protecting function of the quaternary ammonium salt is not sufficiently exhibited.
- vitamin E types are compounded with more than 2.0% by weight, the enhancement action which corresponds to the compounding amount of vitamin E cannot be observed. Further, an excessive amount of vitamin E as stated above causes oxidation with the passage of time, and it is not preferable because of the adverse effect of deteriorated vitamin E types caused by this oxidation, e.g., offensive odor sometimes occurs in a comparatively short period of time.
- the compounding amount of the vitamin E types is in the range from 0.0001% by weight to 0.001% by weight with respect to the whole amount of the external preparation for skin
- the enhancement actions of the quaternary ammonium salt can be observed.
- the compounding amount of the vitamin E types is in the range from 0.5% by weight to 2.0% by weight with respect to the whole amount of the external preparation for skin, the enhancement actions of the skin roughness protecting function and skin roughness improvement function can be observed, there is also a possibility of being made sticky by the vitamin E types which is compounded therein according to the formulation form of the external preparation for skin.
- the combination ratio of the vitamin E types is not limited as long as the compounding amount of the vitamin E types to the external preparation for skin is not deviated from the above-mentioned compounding amounts, it can be combined with discretionary ratios.
- the compounding ratio between the vitamin E types and the quaternary ammonium salt is not limited as long as both of the ingredients are compounded within the preferable compounding range, and it can control properly according to the concrete formulation form.
- the one component is compounded too much and the other is compounded a little, even within the preferable compounding range, it cannot deny the tendency that the property of only one side of the compounding ingredients are reflected excessively in the external preparation for skin of the present invention.
- the effect of the quaternary ammonium salt (I) can be maintained which controls the sticky feel of use by the addition of other compounding ingredients such as humectants, and further can improve moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect synergistically.
- the quaternary ammonium salt (I) is not compounded excessively as to produce the powdery feel of use, to the external preparation, it can provide the external preparation for skin which is given enough moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect.
- vitamin A derivatives which, as like the above-mentioned vitamin E types, can synergistically enhance moisturizing function and skin roughness improvement function of the quaternary ammonium salt by being combined with the quaternary ammonium salt.
- the vitamin A derivatives which can be compounded with the external preparation of the present invention are selected from vitamin A esters such as vitamin A palmitate, vitamin A acetate, and the like. However, said vitamin A derivatives are not limited these listed above. For example, retinol or ether of vitamin A and saccharide as vitamin A derivatives can be compounded with the external preparation for skin in accordance with the present invention.
- vitamin A esters are preferable.
- vitamin A derivatives listed here can be synthesized by the normally and publicly known methods, and can be used the goods in the market.
- vitamin A derivatives have already been widely compounded with external preparations for skin, e.g., for the purposes of protecting the dryness of epidermis and correcting the abnormality of a keratinization.
- the safety of the vitamin A derivatives within the external preparation for skin is already confirmed.
- the compounding amount of the quaternary ammonium salt is in the range from 0.01% by weight to 30% by weight, and more preferably, is in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation for skin.
- the moisturizing function and the skin improvement function of the quaternary ammonium salt become insufficient and the stickiness caused by the addition of other humectants and the like cannot be sufficiently controlled.
- the quaternary ammonium salt is compounded more than 30% by weight with respect to the whole amount of the external preparation, the increase of the effect which corresponds to the increase of the compounding amount cannot be expected.
- the feel of use of external preparation for skin which is compounded with an excessive amount of the quaternary ammonium salt (I) is not preferable because it becomes powdery and unsuitable for skin.
- the quaternary ammonium salt (I) is compounded in the range from 0.01% by weight to 1% by weight with respect to the whole amount of the external preparation for skin, moisturizing function and skin improvement function of the quaternary ammonium salt (I) can be exhibited, but the stickiness feel of use cannot be sufficiently controlled according to the property of the humectants which coexists in the external preparation.
- the quaternary ammonium salt (I) in the range from 20% by weight to 30% by weight with respect to the whole amount of the external preparation for skin in accordance with the present invention, it may have the specific powdery feel of use by compounding of this quaternary ammonium salt (I), according to the formulation form of the external preparation for skin of the present invention.
- the compounding amount of the vitamin A derivatives is in the range from 1 ⁇ 10 -5 % by weight to 5.0% by weight (hereinafter referred to as “preferable compounding range”). More preferably, the compounding amount of the vitamin A derivatives is in the range from 1 ⁇ 10 -4 % by weight to 0.5% by weight (hereinafter, referred to as “optimum compounding range”) with respect to the whole amount of the external preparation for skin.
- the compounding amount of the vitamin A derivatives is less than 1 ⁇ 10 -5 % by weight, it is not preferable because the expected effects by compounding vitamin A derivatives, namely an enhancement actions of moisturizing function, skin roughness improvement function, and skin roughness protecting function of the quaternary ammonium salt are not sufficiently exhibited.
- the vitamin A derivatives are compounded more than 5.0% by weight, the improvement of the enhancement effects which corresponds to the increase of the compounding amount are not observed. Further, an excess amount of the vitamin A derivatives causes oxidation with the passage of time, and it is not preferable because of the adverse effect of deteriorated vitamin A derivatives caused by this oxidation, e.g., offensive odor sometimes occurs in a comparatively short period of time.
- the compounding amount of the vitamin A derivatives is in the rage from 1 ⁇ 10 -5 % by weight to 1 ⁇ 10 -4 % by weight with respect to the whole amount of the external preparation for skin, the above-mentioned effects can be observed.
- the compounding amount of the vitamin A derivatives is in the range from 0.5% by weight to 5.0% by weight with respect to the whole amount of the external preparation for skin, the improvement of skin roughness protecting effect and skin roughness improvement effect can be observed. There is a possibility of being sticky by the compounded vitamin A derivatives according to this formulation form of the external preparation for skin.
- each of the vitamin A derivatives stated above can be compounded separately into the external preparation for skin, and also can be compounded by combining them properly.
- the combination ratio of these vitamin A derivatives is not limited as long as the compounding amount of the vitamin A derivatives to the external preparation for skin is not over the above-mentioned compounding amounts, they can be combined by a discretionary ratio.
- the compounding ratio of the vitamin A derivatives and the quaternary ammonium salt (I) is not limited as long as both of the ingredients are compounded within the above-mentioned preferable compounding range, and it can be adjusted according to its concrete formulation form.
- the one ingredient is compounded too much, and the other is compounded too a little, even within the preferable compounding range, it cannot deny the tendency that the property of only one side of the compounding ingredient is reflected excessively in the external preparation for skin of the present invention.
- the quaternary ammonium salt (I) By compounding the quaternary ammonium salt (I) together with the vitamin A derivatives to the external preparation for skin, it can maintain the effect of the quaternary ammonium salt (I) can be maintained which controls the sticky feel of use by the addition of other compounding ingredients such as humectants, and further can improve moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect synergistically. Namely, even though the quaternary ammonium salt (I) is not compounded excessively until it produces the powdery feel of use, to the external preparation, it can provide the external preparation for skin which is sufficiently given moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect.
- the alkyl denatured carboxyvinyl polymer which is used in the present invention is acrylate methacrylate copolymer, and can be manufactured by normal methods. To be concrete, this alkyl denatured carboxyvinyl polymer is placed on the market as CARBOPOL 1342 (Produced by United States of America B.F. Goodrich Chemical Company Registered Trademark), PEMULEN TR-1 (same as above), PEMULEN TR-2 (same as above), and the like. These are commercially available.
- the quaternary ammonium salt used together with the alkyl denatured carboxyvinyl polymer is compounded in the range from 0.01 to 30% by weight, and more preferably, is compounded in the range from 0.1 to 20% by weight with respect to the whole amount of the composition of the present invention.
- the compounding amount of the quaternary ammonium salt is less than 0.01% by weight, the moisturizing effect and the skin improvement effect of the quaternary ammonium salt is not sufficiently exhibited.
- the quaternary ammonium salt is compounded more than 30% by weight, the increase of the effect which corresponds to the increase of the compounding amount is not expected.
- the alkyl denatured carboxyvinyl polymer is compounded in the range from 0.01 to 5% by weight, and more preferably, is compounded in the range from 0.05 to 2% by weight with respect to the external preparation for skin of the present invention. If the compounding amount is less than 0.01% by weight, the moisturizing effect and the skin improvement effect are not sufficiently exhibited. And in the case where the compounding amount is more than 5% by weight, the viscosity of the composition becomes too high and it sometimes stand out clearly the stickiness with a view of the usability.
- comparative low concentration quaternary ammonium salt and alkyl denatured carboxyvinyl polymer are compounded, namely, in the case where the compounding amount of the quaternary ammonium salt is less than 10% by weight and the compounding amount of the alkyl denatured carboxyvinyl polymer is less than 0.1% by weight, it exhibits relative low viscosity, an excellent moisturizing effect, and a skin improvement effect like the cases which use the vitamin E types and the vitamin A derivatives.
- the compounding amount of the quaternary ammonium salt is more than 10% by weight and the compounding amount of the alkyl denatured carboxyvinyl polymer is more than 0.1% by weight, the system is in a tendency to form gel. However, it is hard to yield the "powdery feeling" of the quaternary ammonium salt relatively, and it is the preferable system in the particular case where is inclined to use the quaternary ammonium salt at high concentrations.
- the alkyl denatured carboxyvinyl polymer is used as the base of gel state products in the field of cosmetics and drugs, it is necessary to neutralize the alkyl denatured carboxyvinyl polymer by basic substance in order to obtain the gel composition.
- it in order to obtain the gel composition which is further given moisturizing effect and skin roughness improvement effect, it has to have added a humectant such as glycerin and other ingredients. Accordingly, in case of making a gel base which has a proper viscosity and also has moisturizing effect and skin roughness improvement effect, it leads to increase the number of the manufacturing process steps, and it also has a problem of being a complicated process of manufacturing.
- the alkyl denatured carboxyvinyl polymer together with the quaternary ammonium salt does not have to neutralize said alkyl denatured carboxyvinyl polymer by basic substance and it also can exhibit moisturizing effect and skin roughness improvement effect.
- the present invention by using vitamin E types, vitamin A derivatives, alkyl denatured carboxyvinyl polymer, and a quaternary ammonium salt (I) as the mixture of the bases which corresponds to the expected formulation form and can be permitted in the preparation, it is possible to exhibit the expected effect of the present invention of "offering the external preparation for skin which is excellent in moisturizing effect, skin roughness improvement effect, skin roughness protecting effect, and feeling of use". There is no particular necessity to compound other additional ingredients, as long as the external preparation for skin is the only intended use of these expected effects.
- the external preparation for skin which is further given a moisturizing effect
- it can be compounded with moisturizing ingredients such as polyethylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerine, sorbitol, xylitol, maltitol, hyaluronic acid, sodium lactate, sodium PCA, chondroitin sulfate, Spanish mackerel extract, peony extract, rumex japonicus houtt, and the like.
- moisturizing ingredients such as polyethylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerine, sorbitol, xylitol, maltitol, hyaluronic acid, sodium lactate, sodium PCA, chondroitin sulfate, Spanish mackerel extract, peony extract, rumex japonicus houtt, and the like.
- vitamin C such as arbutin, kojic acid or ascorbic acid, ascorbyl sulfate (salt), ascorbyl phosphate (salt), ascorbyl dipalmitate, and the like.
- the ingredients are selected from an anti-inflammatory ingredients such as allantoin, glycyrrhizinic acid (salt), glycyrrhetinic acid and its derivatives, glutathione, acyl sarcosinate, tranexamic acid, saponins (e.g., saiko saponin, carrot saponin, sponge cucumber gourd saponin, and the like), glycyrrhiza extract, Japanese coptis extract, shikon extract, yarrow extract, comfrey extract, aloe extract, sorrel extract, nuphar extract, mallow extract, Japanese angelica extract, horsetail extract, saxifrage extract, arnica extract, extract of liliaceae vegetables, mugwort extract, gardenia extract, wild thyme extract, and the like; astringent ingredient such as allantoin, glycyrrhizinic acid (salt), glycyrrhetinic acid and its derivatives,
- vasodilating ingredients such as swertia herb extract, cnidium rhizome extract, sage extract, cephalanthin, ⁇ -oryzanol, benzyl nicotinate, and the like.
- the external preparation for skin which is given an antibacterial effect, it can be compounded with antibacterial ingredients such as hinokitiol, bisabolol, eucalyptol, and the like.
- the external preparation for skin which is given a sebum inhibitory effct, it can be compounded with sebum inhibitory ingredients such as ethynylestradiol, and the like.
- ingredients which can be compounded in the external preparation for skin of the present invention are not limited to these ingredients listed above.
- the pharmaceutical effects which correspond to the above-listed ingredients are not limited to these pharmaceutical effects.
- vitamin C can be used as a whitening ingredient, and it also can be used as assistant antioxidants which will be described later.
- the ingredients which are mentioned above are, except for compounding into the external preparation for skin separately, may be compounded by combining properly more than two kinds of pharmaceutical effect ingredients according to its object.
- the external preparation for skin in accordance with the present invention is widely applicable to cosmetic ingredients, drugs, and quasi drugs, which are applied to the epidermis.
- the formulation form is widely formable such as a water solution type, a solubilization type, an emulsification type, a powder type, an oily liquid type, a gel type, an ointment type, an aerosol type, a water-oil 2 phase type, a water-oil-powder 3 phase type, and the like.
- the external preparation for skin of the present invention can be used as a washing foam, a skin lotion, a milky lotion, a cream, a gel, an essence (skin lotion), a pack mask, and a cosmetic preparation for shaving.
- the external preparation of the present invention is widely suitable for the form such as foundation, rouge, and the like. And further, as for drugs or quasi-drugs, the external preparation of the present invention is widely applicable to the form such as various ointment agent, and the like. However, the external preparation for skin in accordance with the present invention is not limited to these forms or formulation forms.
- normally and publicly known base ingredients can be widely compounded to the external preparation according to the expected forms and formulation forms as long as the compounding of the ingredients does not spoil the effects of the present invention.
- ingredients which are mentioned above are exemplified such as fats and oils, wax esters, ester oil, hydrocarbon oil, silicone, surfactant, lower alcohol, sterol, humectant, water- soluble high polymer, ultraviolet absorbers, sequestering agents, pH adjustor, neutralizer, antioxidants, antibacterial agents, pharmaceutical preparations, various extracts, and the like.
- titanium dioxide titanium dioxide, mica, talc, kaolin, mica coated with titanium dioxide, and the like are exemplified.
- liquid oils and fats such as linseed oil, camellia oil, macadamia nut oil, corn oil, mink oil, olive oil, avocado oil, sasanqua oil, castor oil, safflower oil, apricot kernel oil, cinnamon oil, jojoba oil, grape seed oil, sunflower seed oil, almond oil, rape seed oil, sesame oil, wheat germ oil, rice germ oil, rice bran oil, cottonseed oil, soybean oil, peanut oil, tea oil, evening primrose oil, egg yolk oil, beef leg oil, cod liver oil, triglycerin, trioctanoic acid, glycerine, glyceryl triisopalumitate, and the like; liquid or solid fats and oils such as coconut oil, palm oil, palm kernel oil, and the like; solid fats and oils such as cacao butter, beef tallow, mutton tallow, lard, horseflesh tallow, hydrogenated oil, hydrogenated castor oil, Japan wax
- hydrocarbon oils oily components such as liquid paraffin, ozokerite, squalane, squalene, pristane, paraffin, isoparaffin, ceresin, petrolatum, microcrystalline wax, and the like are exemplified.
- wax esters beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, Chinese wax, spermaceti, montan wax, rice bran wax, lanolin, hydrogenated lanolin, hard lanolin, kapok wax, sugarcane wax, jojoba wax, shellac wax, and the like are exemplified.
- cetanol As for higher alcohols, cetanol, stearyl alcohol, isostearyl alcohol, 2-octyldodecanol, lanolin alcohol, and the like are exemplified.
- lauric acid myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, linolehic acid, linoleic acid, hydroxystearic acid, and the like are exemplified.
- esters of octanoic acid such as cetyl octanoate and the like; esters of isooctanoic acid such as glyceryl tri(2-ethyl hexanoate), pentaerythritol tetra(2-ethylhexanoate), and the like; esters of lauric acid such as hexyl laurate, and the like; esters of myristic acid such as isopropyl myristate, 2-octyldodecyl myristate, and the like; esters of palmitic acid such as octyl palmitate, and the like; esters of stearic acid such as isocetyl stearate, and the like; esters of isostearic acid such as propyl isostearate, and the like; esters of isopalmitic acid such as octyl isopalmitate, and the like; esters of esters of is
- diethylene glycol monopropyl ether polyoxyethylene polyoxypropylene pentaerythritol ether, polyoxypropylene butyl ether, ethyl linoleate, and the like are exemplified.
- silicones chain silicones such as dimethyl polysiloxane, methylphenyl polysiloxane, methyl hydrogen polysiloxane, and the like; cyclic silicones such as octamethyl tetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, and the like, are exemplified.
- water-soluble thickening agents vegetable type water-soluble high polymer such as arabic gum, tragacanth gum, galactene, carob bean gum, guar gum, xanthan gum, caraya gum, carrageenan, pectin, agar, quince seed (quince), algae choloid (algae extract), and the like; microbe type water-soluble high polymer such as dextran, succinoglucan, pullulan, and the like; animal type water-soluble high polymer such as collagen, casein, albumen, gelatin, and the like; cellulose type water-soluble high polymer such as methyl cellulose, nitrocellulose, ethyl cellulose, methylhydroxypropyl cellulose, hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropylcellulose, sodium carboxymethyl cellulose (CMC), microcrystalline cellulose, cellulose powder, and the like; alginic acid type water-soluble high polymer such as sodium alginate, propylene glycol
- sterols cholesterol, ⁇ -sitosterol, phytosterol, lanosterol, and the like are exemplified.
- antioxidants or assistant antioxidants butylhydroxy toluene, tocopherol, butylhydroxyanisol, gallic acid ester, phytic acid, malic acid, and the like are exemplified.
- benzoic acid salicylic acid, sorbic acid, carbolic acid, p-hydroxybenzoic acid alkyl ester (methylparaben, ethylparaben, butylparaben, and the like), benzalkonium chloride, chlorhexidine chloride, trichlorocarbanilide, photosensitizing dye, phenoxyethanol, hexachlorophene, and the like are exemplified.
- nonionic surfactants sorbitan monolaurate, sorbitan sesquioleate, sorbitan tholeate, polyoxyethylene sorbitan monolaurate, polyethylene glycol monooleate, polyoxyethylene alkylether, polyglycol diester, lauroyl diethanolamide, fatty acid isopropanolamide, maltitol hydroxy fatty acid group ether, alkylated polysaccharide, alkylglucoside, sugar ester, pantothenyl ethylether, and the like are exemplified.
- cationic surfactants stearyl trimethyl ammonium chloride, benzalkonium chloride, lauryl amine oxide, and the like are exemplified.
- anionic surfactants sodium palmitate, sodium laurate, potassium lauryl sulfate, triethanolamine alkyl sulfate ether, turkey-red oil, linear dodecylbenzene sulfate, polyoxyethylene hydrogenated castor oil malate, acyl methyl taurate, and the like are exemplified.
- ultraviolet absorbers benzoic acid type ultraviolet absorbers such as p-aminobenzoic acid, and the like; anthranilic acid type ultraviolet absorbers such as methyl anthranilate, and the like; salicylic acid type ultraviolet absorbers such as octyl salicylate, phenyl salicylate, homomenthyl salicylate, and the like; cinnamic acid type ultraviolet absorbers such as isopropyl methoxycinnamate, octyl p-methoxycinnamate, 2-ethylhexyl 4-methoxycinnamate, glyceryl octanoate di-p-methoxycimamate, 3,4,5-trimethoxycinnamate, 3-methyl-4-[methylenebis (trimethylsiloxy) silyl ] butyl, and the like; benzophenone type ultraviolet absorbers such as 2,4-dihydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-
- neutralizers also can be compounded to the external preparation in accordance with the present invention.
- 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1,3-propanediol, potassium hydroxide, sodium hydroxide, triethanolamine, sodium carbonate, and the like are exemplified.
- sodium EDTA sodium EDTA, alanine, sodium EDTA (salt), sodium polyphosphate, sodium metaphosphate, phosphoric acid, and the like are exemplified.
- pH adjustor lactic acid, citric acid, glycollic acid, succinic acid, tartaric acid, dl-malic acid, potassium carbonate, sodium bicarbonate, ammonium bicarbonate, and the like are exemplified.
- refrigerants As for refrigerants, menthol, penny royal oil, peppermint oil, camphor, thymol, inositol, spinlantol, methyl salicylate, and the like are preferable.
- pigments, fragrances, purified water, and the like can be compounded to the external preparation for skin in accordance with the present invention by combining properly.
- fragrances, pigments, and the like can be added to the external preparation for skin of the present invention as occasions demand.
- the water evaporation measurement constant (k) of ion- exchanged water is 0.043.
- An activator (sodium lauryl sulfate) 10% water solution was applied to some portions of the forearms of 10 males of a panel in 3 days, to intentionally make the skin rough and making skin roughness intentionally.
- an activator sodium lauryl sulfate 10% water solution was applied to some portions of the forearms of 10 males of a panel in 3 days, to intentionally make the skin rough and making skin roughness intentionally.
- applying the following-mentioned test sample liquid was applied to the rough skin portion twice in a day and the skin surface state was measured by the replica method 5 days after starting application.
- the skin roughness improvement effect was evaluated by the comparison between the rough skin portion where is applied the test sample liquid and the rough skin portion where is nothing applied after the skin was roughened.
- the skin lotion was prepared according to the formulations shown in Table 1, and the effectiveness of the external preparation for skin of the present invention was studied by doing the above-mentioned water retention test and skin roughness improvement test.
- the skin lotion was manufactured by the ordinary process.
- the inventors have manufactured the skin lotion which is the following Table 2 and Table 3, by the basic formulation as like Table 1. And they further studied about the mutual relation between the quaternary ammonium salt and the vitamin E types.
- Table 2 Test example 1-1 1-2 1-3 1-4 1-5 1-6 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 2.0 2.0 2.0 2.0 2.0 2.0 2.0 dl- ⁇ -tocopherol 0 0.0001 0.001 0.01 0.5 2.0 Purified water balance balance balance balance balance balance balance balance balance Moisturizing effect ⁇ ⁇ o o o o Skin roughness improvement effect ⁇ ⁇ ⁇ o o o
- test examples 1-3 to 1-6 which is compounded trimethylglycine as a quaternary ammonium salt and dl- ⁇ -tocopherol as a vitamin E types with the optimum compounding range, the skin lotion is excellent in both moisturizing effect and skin roughness improvement effect.
- the compounding amount of dl- ⁇ -tocopherol was preferably less than 2.0% by weight.
- the skin lotion which is compounded 0.01% by weight or more of trimethylglycine can obtain moisturizing effect and skin roughness improvement effect, but its remarkable effect is only exhibited in the case where trimethylglycine is compounded 0.1% by weight or more to the skin lotion.
- the moisturizing effect can be improved by compounding other humectants additionally.
- the skin lotion which is compounded dl- ⁇ -tocopherol and trimethylglycine within the optimum compounding range is an excellent skin lotion which can sufficiently exhibit the expected effects.
- vitamin E types except for dl- ⁇ -tocopherol which can be compounded to the external preparation for skin of the present invention is in common with dl- ⁇ -tocopherol in the fundamental pharmaceutical effects as a vitamin E types. Therefore, in case of compounding these other vitamin E types by the formulation which corresponds to the properties of each vitamin E types in place of dl- ⁇ -tocopherol, the excellent skin lotion as the test examples is provided.
- the milky lotion in accordance with the example 1 which are compounded the quaternary ammonium salt (trimethylglycine) and the vitamin E types (vitamin E acetate) within the optimum compounding range, are particular excellent in both moisturizing effect and skin roughness improvement effect.
- the milky lotion of the example 2 become inconspicuous in skin roughness improvement effect. But, the milky lotion worked sufficiently according to the expected effect of the present invention.
- the milky lotion in accordance with the example 3 is slightly inferior in moisturizing effect.
- the moisturizing effect of trimethylglycine may not appear remarkably because that the compounding amount of trimethylglycine has not reached to the optimum compounding range (though the compounding amount of trimethylglycine is within the preferable compounding range).
- the moisturizing property can be improved by compounding other humectants to this milky lotion.
- comparative example 2 which was compounded vitamin E acetate and was not compounded with any quaternary ammonium salt (I), did not exhibit the effect of the present invention as like comparative example 1.
- comparative example 3 which was not compounded with both the vitamin E types and the quaternary ammonium salt (I) (needless to say) did not exhibit the effect of the present invention.
- the milky lotion which was compounded vitamin E acetate as vitamin E types and trimethylglycine as quaternary ammonium salt (I) within the optimum compounding range, sufficiently exhibited the expected effect.
- the milky lotion which was compounded vitamin E acetate (vitamin E types) and trimethylglycine (quaternary ammonium salt) within the preferable compounding range, was sufficiently fit for use, in view of the exhibition of the expected effect.
- vitamin E types except for vitamin E acetate which can be compounded to the already-described external preparation for skin is in common with vitamin E acetate in the fundamental pharmaceutical effects as the vitamin E types. Therefore, in case of compounding these other vitamin E types by the formulation which corresponds to the properties of each vitamin E types in place of vitamin E acetate, the excellent milky lotion as like said examples can be provided.
- test examples 2-3 to 2-6 which were compounded trimethylglycine as a quaternary ammonium salt and vitamin A palmitate as a vitamin A derivatives within the optimum compounding range, the skin lotion was excellent in both moisturizing effect and skin roughness improvement effect.
- the compounding amount of vitamin A palmitate is preferably 5.0% by weight or less.
- test example 2-2 was compounded with a relative small amount of vitamin A palmitate as compared with the skin lotion of test examples 2-3 to 2-6, the skin roughness improvement effect of the skin lotion became inconspicuous. However the skin lotion was sufficiently worked the expected effect of the present invention.
- the skin lotion which was compounded these within the preferable compounding range was a skin lotion which was sufficiently fitted for practical use in view of the exhibition of the expected effect.
- vitamin A derivatives except for vitamin A palmitate which can be compounded to the described external preparation for skin of the present invention is in common with vitamin A palmitate in the basic pharmaceutical effects as a vitamin A derivatives. Therefore, in case of compounding these other vitamin A derivatives by the formulation which corresponds to the properties of each vitamin A derivative in place of vitamin A palmitate, an excellent skin lotion can be provided like the above-mentioned test examples.
- milky lotion was prepared by the formulation of the following described Table 7, the effectiveness of the external preparation for skin of the present invention was studied by doing the above-described water retention test and skin roughness improvement test.
- Table 7 Example 2-1 2-2 (Oil phase) Squalane 10.0 10.0 Petrolatum 2.0 2.0 Cetanol 1.0 1.0 Lanolin alcohol 2.0 2.0 Liquid paraffin 8.0 8.0 Vitamin A acetate 0.001 1 ⁇ 10 -4 Antiseptic agent 0.2 0.2 Perfume 0.05 0.05 (Water phase) Carboxyvinyl polymer 0.2 0.2 Alkyl denatured carboxyvinyl polymer 0.7 0.7 KOH 0.3 0.3 ⁇ -Butyroglycin 5.0 5.0 Purified water balance balance Moisturizing effect o o Skin roughness improvement effect o ⁇
- the milky lotion in accordance with the example 2-1 which was compounded ⁇ -butyroglycin as a quaternary ammonium salt (I) and vitamin A acetate as a vitamin E types within the optimum compounding range was particularly excellent in both moisturizing effect and skin roughness improvement effect.
- the milky lotion in accordance with the example 2-2 became inconspicuous in skin roughness improvement effect. But, the milky lotion was sufficiently worked the expected effect of the present invention.
- the milky lotion which was compounded the vitamin A derivatives and the quaternary ammonium salt (I) within the optimum compounding range, can sufficiently exhibit the expected effect.
- the milky lotion which was compounded the vitamin A derivatives and the quaternary ammonium salt within the preferable compounding range, was sufficiently fitted for practical use in view of exhibiting the expected effect.
- the inventors manufactured the composition which is described in Table 8 and Table 9, and the study further proceeded about the mutual relation between the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer.
- the composition In case of using combined a quaternary ammonium salt and alkyl denatured carboxyvinyl polymer, if both the components are low concentrations, the composition is in a liquid state. However, if both the components are high concentrations, the composition forms a gel. This gel formative action is the phenomenon which is differentially seen by the combination of the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer. This gel formative action has been done by the following test.
- the viscosity of each samples was measured by a roater No. at 30°C by using a single cylindrical rotating viscometer (VS-A1 type) produced by Seiki Kogyo Kenkyusho (Co.,ltd.). This viscosity was evaluated as the indication of the gel formative property.
- ethanol phase Polyoxyethylene oleyl ether and methylparaben were dissolved into ethanol (ethanol phase). Aside from this, the dissolution (water phase) was prepared by dissolving alkyl denatured carboxyvinyl polymer and trimethylglycine into ion-exchanged water. And then, the ethanol phase was added to the water phase and the skin lotion was obtained by solubilizing and dissolving it.
- test examples 3-3 to 2-6 which were compounded trimethylglycine as the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer within the optimum compounding range, the skin lotion was excellent in both moisturizing effect and skin roughness improvement effect. However in test example 2-6, since the skin lotion had a tendency to worsen the feel of use because the gel viscosity become too high.
- the amount of alkyl denatured carboxyvinyl polymer is preferably 5.0% by weight or less.
- trimethylglycine is compounded 30.0% by weight or more, the slight powdery feeling was appeared.
- the skin lotion which was compounded alkyl denatured carboxyvinyl polymer and trimethylglycine as the quaternary ammonium salt (I) within the optimum compounding range was an excellent skin lotion which was sufficiently exhibited the expected effect.
- Example 3-1 was formed the proper viscosity gel without using the base (potassium hydroxide) as a neutralizer, and the moisturizing effect was observed to be stronger than comparative example 3-2 which was compounded a humectant.
- Alcohol phase POE oleyl alcohol ether 1.0 Olive oil 0.2 Antiseptic agent 0.2 Ethyl alcohol 7.0 Vitamin E acetate 0.1 Water phase Sorbitol 8.0 1,3 Butylene glycol 5.0 Polyethylene glycol 1500 7.0 Hyaluronic acid 0.1 Trimethylglycine 2.0 Purified water balance
- the water phase was obtained by dissolving the above-stated water phase components to purified water. Next, POE oleyl ether, olive oil, and antiseptic agent were dissolved into ethanol successively. After heating and dissolving a soluble antiseptic agent to dipropylene glycol, and solubilizing methyl cellulose and the expected skin lotion was obtained.
- Alcohol phase POE oleyl alcohol ether 1.0 Olive oil 0.2 Antiseptic agent 0.2 Ethyl alcohol 7.0 Vitamin A palmitate 0.01 Water phase Sorbitol 8.0 1,3 Butylene glycol 5.0 Polyethylene glycol 1500 7.0 Hyaluronic acid 0.1 ⁇ -Butyrobetaine 2.0 Purified water balance
- the water phase was obtained by dissolving the above-stated water phase component to purified water. Next, POE oleyl ether, olive oil, and antiseptic agent were dissolved into ethanol successively. After heating and dissolving a soluble antiseptic agent to dipropylene glycol, and solubilizing methyl cellulose, the expected skin lotion was obtained.
- Oil phase Squalane 10.0 Isopropyl palmitate 5.0 POE (25) cetyl ether 0.5 Petrolatum 3.0 Dimethyl polysiloxane 2.0 Hexyldecanol 3.0 ⁇ -tocopherol 0.3
- phase A oil phase
- phase B water phase
- the obtained emulsion composition had good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
- Oil phase Liquid paraffin 10.0 Jojoba oil 4.0 Dimethyl polysiloxane (10cs) 3.0 POE (15) sorbitan monostearate 1.0 Glyceryl monostearate 0.5 Vitamin A oil 3.0
- Magnesium ascorbyl phosphate 1.0 Placenta extract 0.5
- Trisodium EDTA 0.15 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 0.15 Methylparabenzoate 0.1 Phenoxyethanol 0.2 ⁇ -Butyrobetaine 0.1 Ion-exchanged water balance
- phase A oil phase
- phase B water phase
- the obtained emulsion composition had a good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
- Oil phase Stearic acid 2.0 Cetyl alcohol 1.5 Petrolatum 4.0 Squalane 5.0 Glycerol tri(2-ethylhexanoate) 2.0 Sorbitan monooleate 2.0 2-ethylhexyl 4-methoxycinnamate 2.0 dl-tocopheryl acetate 0.5 Ethyl parahydroxybenzoate 0.1
- Water phase Dipropylene glycol 5.0 Polyethylene glycol (1500) 0.15 Trisodium EDTA 5.0 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 5.0 Carboxy methyl cellulose 0.8 Trimethylglycine 10.0 Potassium hydroxide 1.0 Ion-exchanged water balance
- phase B Using a part of ion-exchanged water of phase B, and the gel was formed by dissolving [CARBOPOL 1342] and trimethylglycine into this.
- Phase A oil phase
- Phase B water phase; except for [CARBOPOL 1342] and trimethylglycine
- the obtained emulsion composition had a good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
- Sorbitol 4.0 Dipropylene glycol 6.0 Polyethylene glycol 5.0 Ethanol 10.0 POE (20) oleyl alcohol ether 0.5 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 0.15 ⁇ -Butyrobetaine 0.8 Ion-exchanged water balance
- the obtained solubilizing composition had a good gel formative property (viscosity) and excellent moisturizing property, and also had a skin roughness improvement effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to an external preparation for skin and in particular, relates to an enhancer of betaine which has a moisturizing function and a skin improvement function.
- A maintenance function of a beautiful skin state is one of the fundamental functions of an external preparation for skin such as cosmetics. In order to maintain this beautiful skin state, it is essential to condition the sulci cutis and cristae of the skin by preventing or improving a skin roughness.
- In order to attain this object, various humectants such as glycerin, sorbitol, propylene glycol, polysaccharide, and the like have been compounded into cosmetics.
- However, among these humectants, e.g., polysaccharide may cause precipitation in the formulation which contains a large amounts of alcohol. Cosmetics which are compounded with glycerin, sorbitol, propylene glycol, and the like in large amounts for the purpose of improving the moisturizing effect, have a tendency to be attended with the sticky feel of use.
- In order to remove the sticky feel of use of the cosmetics which is attendant to the improvement of the moisturizing effect, an experiment of compounding trimethylglycine (quaternary ammonium salt) into a cosmetic has been done (cf. Japanese Unexamined Patent Publication Hei No. 6-293625).
- A cosmetic which is compounded with trimethylglycine independently can reduce the sticky feel of use. However, in the case where trimethylglycine is compounded in the dosage which is enough to exhibit the improvement effect of the skin state that trimethylglycine is possessed, such an external preparation for skin has a tendency to be attended with "powdery feel of use" by the presence of trimethylglycine. Therefore, the external preparation for skin which is compounded trimethylglycine independently, does not sufficiently satisfy the requirements of users.
- In view of the above- mentioned problem of the prior art, the object of the present invention is to provide an external preparation for skin which can sufficiently exhibit the moisturizing function and the skin improvement function of trimethylglycine.
- As the result of diligent studies of the inventors for attaining the above-mentioned object, it has been found that coexistence with a specific high-molecular components or vitamins, can largely improve the moisturizing function and the skin improvement function that the low-molecular-weight betaine is normally possessed. Accordingly, the present invention has been accomplished.
- Namely, the present invention provides an external preparation for skin comprising a quaternary ammonium salt which is shown by following constitutional formula (I), and, an enhancer of the moisturizing function, and the skin improvement function of a quaternary ammonium salt selected from the group consisting of vitamin E types, vitamin A derivatives, and alkyl denatured carboxyvinyl polymer.
- Preferably, the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 30% by weight with respect to the whole amount of the external preparation.
- More preferably, the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- Preferably, vitamin E types are tocopherol and/or vitamin E acetate.
- Also preferably, the compounding amount of the vitamin E types is in the range from 0.0001% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
- More preferably, the compounding amount of the vitamin E types is in the range from 0.001% by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- Preferably, vitamin A derivatives are vitamin A ester.
- Also preferably, the compounding amount of the vitamin A derivatives is in the range from 1 × 10-5% by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- Further preferably, the compounding amount of the vitamin A derivatives is in the range from 1 × 10-4% by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- Preferably, the compounding amount of the alkyl denatured carboxyvinyl polymer is in the range from 0.01% by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- More preferably, the compounding amount of the alkyl denatured carboxyvinyl polymer is in the range from 0.05% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
- In the following, the constitution of the present invention will be explained in further detail.
- Firstly, it will be explained about quaternary ammonium salt which is characteristic in the present invention.
- A quaternary ammonium salt which is shown in constitutional formula (I) and compounded with the external preparation for skin of the present invention is a mode of the molecule which is generally called "betaine".
- In formula (I), R1, R2, and R3 show alkyl groups having a carbon number from 1 to 6. And also, a sum total of the carbon number of R1, R2, R3, and n (which is integer 0 or more) is 8 or less.
- If the sum total of the carbon number becomes 9 or more, and the molecular weight of the part of nitrogen atom and the alkyl groups (R1, R2, and R3) which is combined with this nitrogen atom becomes relatively large in a quaternary ammonium salt (I), the hydrophobic nature of the above-mentioned part is increased. This is not preferred since the property of the quaternary ammonium salt as an amphoteric surfactant tend to be actualized.
- As for the Alkyl groups having a carbon number from 1 to 6, the straight chain alkyl group or branched chain alkyl group of said carbon number can be widely applied. Namely, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert-pentyl group, a hexyl group, an isohexyl group, a 3-methylpentyl group, a 2,2-dimethylbutyl group, a 2,3-dimethylbutyl group, and the like can be exemplified as the alkyl group which has said carbon number.
- And, the carbon number of R1, R2, and R3 can be same or different.
- As for the combination of the alkyl groups, in the tendency to reduce the property of the quaternary ammonium salt as an amphoteric surfactant as much as possible, it is preferable to decrease the carbon number of R1, R2, and R3 as little as possible. Therefore, it is preferable in the case where the combination of all alkyl groups of the quaternary ammonium salt (I) are methyl groups at the same time, and n is 0, namely, it is more preferable to compound trimethylglycine or γ-butyrobetaine (that all alkyl groups are methyl groups at the same time and n is 2) as a quaternary ammonium salt. And also, trimethylglycine and γ-butyrobetaine are known to be widely distributed in the animal and vegetable kingdoms, and they are the preferable quaternary ammonium salt for planning a physiologically beautiful skin state as much as possible.
- Next, it will be explained about vitamin E types which can synergistically enhance the moisturizing function and the skin improvement function of the quaternary ammonium salt by combining it with the quaternary ammonium salt.
- Examples of the vitamin E types which can be compounded for the external preparation of the present invention are selected from vitamin E such as natural vitamin E, α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol; vitamin E derivatives such as vitamin E acetate, vitamin E nicotinate, α-tocopherol-2, L- ascorbic acid phosphate diester; the salt of these, and the like.
- These examples of vitamin E types listed here are comprised of, needless to say d-isomer which ordinarily exists in nature, and optical isomers that can be synthesized such as l-isomer, or dl-isomer which is the mixture of d-isomer and l-isomer. In the case where we are referring to vitamin E types in the present invention, unless otherwise stated, it comprises all these possibilities.
- Further, if the external preparation has a formulation form which is desired to be transparent (e.g., water solution type or solubilization type), it is preferable to compound the water soluble vitamin E derivatives by selecting from among these vitamin E types, in view of making the transparency better.
- The vitamin E types listed here can be synthesized by the publicly known methods (e.g., Trost method) and can also use vitamin E purchased in the market.
- In the external preparation for skin of the present invention, if vitamin E types are used as an enhancer of moisturizing function and skin improvement function, the compounding amount of the above- mentioned quaternary ammonium salt (I) is preferably in the range from 0.01% by weight to 30% by weight, and more preferably in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation. In case of compounding a quaternary ammonium salt into a skin lotion, by compounding about 8.0% by weight of the quaternary ammonium salt, the sufficient effect can be exhibited. In the case where the compounding amount is less than 0.01% by weight, the moisturizing function and the skin improvement function of the quaternary ammonium salt becomes insufficient, and it cannot sufficiently control the stickiness which is caused by the addition of other humectants. Also, even though a quaternary ammonium salt is compounded with 30% by weight or more, the effective increase which corresponds to the increase of the compounding amount cannot be expected. The feel of use of external preparation for skin which is compounded with such an excessive amount of the quaternary ammonium salt (I) is powdery and is not preferable because of the deteriorating of suitability for skin.
- Also, if the quaternary ammonium salt (I) is compounded in the range from 0.01% by weight to 1% by weight with respect to the whole amount of the external preparation for skin, it generally exhibits the moisturizing function and skin improvement function of the quaternary ammonium salt (I). However, it sometimes cannot sufficiently control the sticky feel of use, according to the property of other humectants with which it coexists.
- Further, if the quaternary ammonium salt (I) is compounded in the range from 20% by weight to 30% by weight with respect to the whole amount of the external preparation for skin in accordance with the present invention, a specific powdery feel of use is possible by compounding of this quaternary ammonium salt (I), according to the formulation form.
- Preferably, the compounding amount of the vitamin E types which are compounded to the external preparation for skin in accordance with the present invention is in the range from 0.0001% by weight to 2.0% by weight with respect to the whole amount of the external preparation for skin (hereinafter, when this application refers to as "preferable compounding range", as shown in here, it means the preferable compounding range of the compounding ingredients for the external preparation for skin of the present invention). More preferably, the compounding amount of the vitamin E types is in the range from 0.001% by weight to 0.5% by weight with respect to the whole amount of the external preparation for skin (hereinafter, when this application refers to as "optimum compounding range", as shown in here, it means the more preferable compounding range of the compounding ingredients of the external preparation for skin in accordance with the present invention).
- If the compounding amount of the vitamin E types is less than 0.0001% by weight, it is not preferable because the enhancement actions of moisturizing function, skin roughness improvement function, and skin roughness protecting function of the quaternary ammonium salt is not sufficiently exhibited.
- And also, if vitamin E types are compounded with more than 2.0% by weight, the enhancement action which corresponds to the compounding amount of vitamin E cannot be observed. Further, an excessive amount of vitamin E as stated above causes oxidation with the passage of time, and it is not preferable because of the adverse effect of deteriorated vitamin E types caused by this oxidation, e.g., offensive odor sometimes occurs in a comparatively short period of time.
- And further, in the case where the compounding amount of the vitamin E types is in the range from 0.0001% by weight to 0.001% by weight with respect to the whole amount of the external preparation for skin, the enhancement actions of the quaternary ammonium salt can be observed. However, for the purpose of exhibiting the enhancement effect sufficiently, it need to take account of making the compounding amount of the quaternary ammonium salt enlarge relatively. In this case, it cannot deny a possibility of being accompanied this specific powdery feel of use of the quaternary ammonium salt according to this formulation form.
- And, in the case where the compounding amount of the vitamin E types is in the range from 0.5% by weight to 2.0% by weight with respect to the whole amount of the external preparation for skin, the enhancement actions of the skin roughness protecting function and skin roughness improvement function can be observed, there is also a possibility of being made sticky by the vitamin E types which is compounded therein according to the formulation form of the external preparation for skin.
- Each vitamin E types stated above can be compounded separately, and also can be compounded by combining properly.
- The combination ratio of the vitamin E types is not limited as long as the compounding amount of the vitamin E types to the external preparation for skin is not deviated from the above-mentioned compounding amounts, it can be combined with discretionary ratios.
- The compounding ratio between the vitamin E types and the quaternary ammonium salt is not limited as long as both of the ingredients are compounded within the preferable compounding range, and it can control properly according to the concrete formulation form. However, in the case where the one component is compounded too much and the other is compounded a little, even within the preferable compounding range, it cannot deny the tendency that the property of only one side of the compounding ingredients are reflected excessively in the external preparation for skin of the present invention.
- By compounding the quaternary ammonium salt (I) with the vitamin E types to the external preparation for skin, the effect of the quaternary ammonium salt (I) can be maintained which controls the sticky feel of use by the addition of other compounding ingredients such as humectants, and further can improve moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect synergistically. Namely, even though the quaternary ammonium salt (I) is not compounded excessively as to produce the powdery feel of use, to the external preparation, it can provide the external preparation for skin which is given enough moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect.
- Next, it will be explained that vitamin A derivatives which, as like the above-mentioned vitamin E types, can synergistically enhance moisturizing function and skin roughness improvement function of the quaternary ammonium salt by being combined with the quaternary ammonium salt.
- The vitamin A derivatives which can be compounded with the external preparation of the present invention are selected from vitamin A esters such as vitamin A palmitate, vitamin A acetate, and the like. However, said vitamin A derivatives are not limited these listed above. For example, retinol or ether of vitamin A and saccharide as vitamin A derivatives can be compounded with the external preparation for skin in accordance with the present invention.
- However, in considering the stability and the like within the external preparation for skin, vitamin A esters are preferable.
- Each of vitamin A derivatives listed here can be synthesized by the normally and publicly known methods, and can be used the goods in the market.
- Further, these vitamin A derivatives have already been widely compounded with external preparations for skin, e.g., for the purposes of protecting the dryness of epidermis and correcting the abnormality of a keratinization. The safety of the vitamin A derivatives within the external preparation for skin is already confirmed.
- In the external preparation for skin in accordance with the present invention, in the case where the vitamin A derivatives are used as an enhancer for moisturizing function and skin improvement function of the quaternary ammonium salt, preferably, the compounding amount of the quaternary ammonium salt is in the range from 0.01% by weight to 30% by weight, and more preferably, is in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation for skin. In the case where the compounding amount of the quaternary ammonium salt is less than 0.01% by weight with respect to the whole amount of the external preparation for skin, the moisturizing function and the skin improvement function of the quaternary ammonium salt become insufficient and the stickiness caused by the addition of other humectants and the like cannot be sufficiently controlled. Also, in the case where the quaternary ammonium salt is compounded more than 30% by weight with respect to the whole amount of the external preparation, the increase of the effect which corresponds to the increase of the compounding amount cannot be expected. And further, the feel of use of external preparation for skin which is compounded with an excessive amount of the quaternary ammonium salt (I) is not preferable because it becomes powdery and unsuitable for skin.
- In the case where the quaternary ammonium salt (I) is compounded in the range from 0.01% by weight to 1% by weight with respect to the whole amount of the external preparation for skin, moisturizing function and skin improvement function of the quaternary ammonium salt (I) can be exhibited, but the stickiness feel of use cannot be sufficiently controlled according to the property of the humectants which coexists in the external preparation.
- Further, in the case where the quaternary ammonium salt (I) is compounded in the range from 20% by weight to 30% by weight with respect to the whole amount of the external preparation for skin in accordance with the present invention, it may have the specific powdery feel of use by compounding of this quaternary ammonium salt (I), according to the formulation form of the external preparation for skin of the present invention.
- Preferably, the compounding amount of the vitamin A derivatives is in the range from 1 × 10-5% by weight to 5.0% by weight (hereinafter referred to as "preferable compounding range"). More preferably, the compounding amount of the vitamin A derivatives is in the range from 1 × 10-4% by weight to 0.5% by weight (hereinafter, referred to as "optimum compounding range") with respect to the whole amount of the external preparation for skin.
- In the case where the compounding amount of the vitamin A derivatives is less than 1 × 10-5% by weight, it is not preferable because the expected effects by compounding vitamin A derivatives, namely an enhancement actions of moisturizing function, skin roughness improvement function, and skin roughness protecting function of the quaternary ammonium salt are not sufficiently exhibited.
- Even if the vitamin A derivatives are compounded more than 5.0% by weight, the improvement of the enhancement effects which corresponds to the increase of the compounding amount are not observed. Further, an excess amount of the vitamin A derivatives causes oxidation with the passage of time, and it is not preferable because of the adverse effect of deteriorated vitamin A derivatives caused by this oxidation, e.g., offensive odor sometimes occurs in a comparatively short period of time.
- Further, in the case where the compounding amount of the vitamin A derivatives is in the rage from 1 × 10-5% by weight to 1 × 10-4% by weight with respect to the whole amount of the external preparation for skin, the above-mentioned effects can be observed. However, in order to sufficiently exhibit the above-mentioned effect, it need to take account of making the compounding amount of the quaternary ammonium salt enlarge relatively. In this case, according to the formulation form of the external preparation for skin, it cannot deny the possibility of being accompanied the specific powdery feel of use of the quaternary ammonium salt.
- In the case where the compounding amount of the vitamin A derivatives is in the range from 0.5% by weight to 5.0% by weight with respect to the whole amount of the external preparation for skin, the improvement of skin roughness protecting effect and skin roughness improvement effect can be observed. There is a possibility of being sticky by the compounded vitamin A derivatives according to this formulation form of the external preparation for skin.
- Also, each of the vitamin A derivatives stated above can be compounded separately into the external preparation for skin, and also can be compounded by combining them properly.
- The combination ratio of these vitamin A derivatives is not limited as long as the compounding amount of the vitamin A derivatives to the external preparation for skin is not over the above-mentioned compounding amounts, they can be combined by a discretionary ratio.
- The compounding ratio of the vitamin A derivatives and the quaternary ammonium salt (I) is not limited as long as both of the ingredients are compounded within the above-mentioned preferable compounding range, and it can be adjusted according to its concrete formulation form. However, in the case where the one ingredient is compounded too much, and the other is compounded too a little, even within the preferable compounding range, it cannot deny the tendency that the property of only one side of the compounding ingredient is reflected excessively in the external preparation for skin of the present invention.
- By compounding the quaternary ammonium salt (I) together with the vitamin A derivatives to the external preparation for skin, it can maintain the effect of the quaternary ammonium salt (I) can be maintained which controls the sticky feel of use by the addition of other compounding ingredients such as humectants, and further can improve moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect synergistically. Namely, even though the quaternary ammonium salt (I) is not compounded excessively until it produces the powdery feel of use, to the external preparation, it can provide the external preparation for skin which is sufficiently given moisturizing effect, skin roughness improvement effect, and skin roughness protecting effect.
- The alkyl denatured carboxyvinyl polymer which is used in the present invention is acrylate methacrylate copolymer, and can be manufactured by normal methods. To be concrete, this alkyl denatured carboxyvinyl polymer is placed on the market as CARBOPOL 1342 (Produced by United States of America B.F. Goodrich Chemical Company Registered Trademark), PEMULEN TR-1 (same as above), PEMULEN TR-2 (same as above), and the like. These are commercially available.
- In the present invention, preferably, the quaternary ammonium salt used together with the alkyl denatured carboxyvinyl polymer is compounded in the range from 0.01 to 30% by weight, and more preferably, is compounded in the range from 0.1 to 20% by weight with respect to the whole amount of the composition of the present invention. In the case where the compounding amount of the quaternary ammonium salt is less than 0.01% by weight, the moisturizing effect and the skin improvement effect of the quaternary ammonium salt is not sufficiently exhibited. And even if the quaternary ammonium salt is compounded more than 30% by weight, the increase of the effect which corresponds to the increase of the compounding amount is not expected.
- In the present invention, preferably, the alkyl denatured carboxyvinyl polymer is compounded in the range from 0.01 to 5% by weight, and more preferably, is compounded in the range from 0.05 to 2% by weight with respect to the external preparation for skin of the present invention. If the compounding amount is less than 0.01% by weight, the moisturizing effect and the skin improvement effect are not sufficiently exhibited. And in the case where the compounding amount is more than 5% by weight, the viscosity of the composition becomes too high and it sometimes stand out clearly the stickiness with a view of the usability.
- In particular, in the case where comparative low concentration quaternary ammonium salt and alkyl denatured carboxyvinyl polymer are compounded, namely, in the case where the compounding amount of the quaternary ammonium salt is less than 10% by weight and the compounding amount of the alkyl denatured carboxyvinyl polymer is less than 0.1% by weight, it exhibits relative low viscosity, an excellent moisturizing effect, and a skin improvement effect like the cases which use the vitamin E types and the vitamin A derivatives.
- On the other hand, if the compounding amount of the quaternary ammonium salt is more than 10% by weight and the compounding amount of the alkyl denatured carboxyvinyl polymer is more than 0.1% by weight, the system is in a tendency to form gel. However, it is hard to yield the "powdery feeling" of the quaternary ammonium salt relatively, and it is the preferable system in the particular case where is inclined to use the quaternary ammonium salt at high concentrations.
- Namely, in the case where the alkyl denatured carboxyvinyl polymer is used as the base of gel state products in the field of cosmetics and drugs, it is necessary to neutralize the alkyl denatured carboxyvinyl polymer by basic substance in order to obtain the gel composition. In addition to this, in order to obtain the gel composition which is further given moisturizing effect and skin roughness improvement effect, it has to have added a humectant such as glycerin and other ingredients. Accordingly, in case of making a gel base which has a proper viscosity and also has moisturizing effect and skin roughness improvement effect, it leads to increase the number of the manufacturing process steps, and it also has a problem of being a complicated process of manufacturing.
- As compared with this, by using the alkyl denatured carboxyvinyl polymer together with the quaternary ammonium salt, as like the present invention, it does not have to neutralize said alkyl denatured carboxyvinyl polymer by basic substance and it also can exhibit moisturizing effect and skin roughness improvement effect.
- In the present invention, by using vitamin E types, vitamin A derivatives, alkyl denatured carboxyvinyl polymer, and a quaternary ammonium salt (I) as the mixture of the bases which corresponds to the expected formulation form and can be permitted in the preparation, it is possible to exhibit the expected effect of the present invention of "offering the external preparation for skin which is excellent in moisturizing effect, skin roughness improvement effect, skin roughness protecting effect, and feeling of use". There is no particular necessity to compound other additional ingredients, as long as the external preparation for skin is the only intended use of these expected effects.
- However, to compound other ingredients for the purpose of giving the effects that the external preparation for skin will generally acts, is possible as long as the expected effects of the present invention are not spoiled by this compounding.
- For example, in case of intending the external preparation for skin which is further given a moisturizing effect, it can be compounded with moisturizing ingredients such as polyethylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerine, sorbitol, xylitol, maltitol, hyaluronic acid, sodium lactate, sodium PCA, chondroitin sulfate, Spanish mackerel extract, peony extract, rumex japonicus houtt, and the like.
- In obtaining an external preparation for skin which is given a whitening effect, it can be compounded with a whitening ingredients of vitamin C such as arbutin, kojic acid or ascorbic acid, ascorbyl sulfate (salt), ascorbyl phosphate (salt), ascorbyl dipalmitate, and the like.
- In obtaining an external preparation for skin which is further given a skin roughness protecting effect, it can be compounded with the ingredients which have a skin roughness protecting action. The ingredients are selected from an anti-inflammatory ingredients such as allantoin, glycyrrhizinic acid (salt), glycyrrhetinic acid and its derivatives, glutathione, acyl sarcosinate, tranexamic acid, saponins (e.g., saiko saponin, carrot saponin, sponge cucumber gourd saponin, and the like), glycyrrhiza extract, Japanese coptis extract, shikon extract, yarrow extract, comfrey extract, aloe extract, sorrel extract, nuphar extract, mallow extract, Japanese angelica extract, horsetail extract, saxifrage extract, arnica extract, extract of liliaceae vegetables, mugwort extract, gardenia extract, wild thyme extract, and the like; astringent ingredient such as citric acid, malic acid, tartaric acid, orange/ bitter orange peel / birch extract, hamamelis extract, white nettle extract, birch bark extract, rhubarb extract; vitamins such as vitamin A, vitamin B (e.g., vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 and its derivatives, vitamin B12, vitamin B15 and its derivatives, and the like), vitamin D, vitamin H, pantothenic acid, pantethine, nicotinamide, and the like; natural products extract such as ginseng extract, lilly extract, sponge cucumber gourd extract, human placental extract and the like.
- In obtaining an external preparation for skin which is given a vasodilating effect, it can be compounded with vasodilating ingredients such as swertia herb extract, cnidium rhizome extract, sage extract, cephalanthin, γ-oryzanol, benzyl nicotinate, and the like.
- In obtaining the external preparation for skin which is given an antibacterial effect, it can be compounded with antibacterial ingredients such as hinokitiol, bisabolol, eucalyptol, and the like.
- In obtaining the external preparation for skin which is given a sebum inhibitory effct, it can be compounded with sebum inhibitory ingredients such as ethynylestradiol, and the like.
- And, the ingredients which can be compounded in the external preparation for skin of the present invention, are not limited to these ingredients listed above. And also, the pharmaceutical effects which correspond to the above-listed ingredients, are not limited to these pharmaceutical effects. For example, vitamin C can be used as a whitening ingredient, and it also can be used as assistant antioxidants which will be described later. Further, the ingredients which are mentioned above are, except for compounding into the external preparation for skin separately, may be compounded by combining properly more than two kinds of pharmaceutical effect ingredients according to its object.
- The external preparation for skin in accordance with the present invention is widely applicable to cosmetic ingredients, drugs, and quasi drugs, which are applied to the epidermis. And the formulation form is widely formable such as a water solution type, a solubilization type, an emulsification type, a powder type, an oily liquid type, a gel type, an ointment type, an aerosol type, a water-oil 2 phase type, a water-oil-powder 3 phase type, and the like. Namely, as for fundamental cosmetics, the external preparation for skin of the present invention can be used as a washing foam, a skin lotion, a milky lotion, a cream, a gel, an essence (skin lotion), a pack mask, and a cosmetic preparation for shaving. And as for make up cosmetics, the external preparation of the present invention is widely suitable for the form such as foundation, rouge, and the like. And further, as for drugs or quasi-drugs, the external preparation of the present invention is widely applicable to the form such as various ointment agent, and the like. However, the external preparation for skin in accordance with the present invention is not limited to these forms or formulation forms.
- In the external preparation for skin in accordance with the present invention, normally and publicly known base ingredients can be widely compounded to the external preparation according to the expected forms and formulation forms as long as the compounding of the ingredients does not spoil the effects of the present invention. In particular, in case of compounding oily base ingredients to the external preparation for skin, it is desirable to compound within the range that the specific stickiness of the base ingredients does not spoil the feel of use of the external preparation for skin in accordance with the present invention.
- The ingredients which are mentioned above are exemplified such as fats and oils, wax esters, ester oil, hydrocarbon oil, silicone, surfactant, lower alcohol, sterol, humectant, water- soluble high polymer, ultraviolet absorbers, sequestering agents, pH adjustor, neutralizer, antioxidants, antibacterial agents, pharmaceutical preparations, various extracts, and the like.
- Namely, as for powder ingredients, titanium dioxide, mica, talc, kaolin, mica coated with titanium dioxide, and the like are exemplified.
- As for fats and oils, liquid oils and fats such as linseed oil, camellia oil, macadamia nut oil, corn oil, mink oil, olive oil, avocado oil, sasanqua oil, castor oil, safflower oil, apricot kernel oil, cinnamon oil, jojoba oil, grape seed oil, sunflower seed oil, almond oil, rape seed oil, sesame oil, wheat germ oil, rice germ oil, rice bran oil, cottonseed oil, soybean oil, peanut oil, tea oil, evening primrose oil, egg yolk oil, beef leg oil, cod liver oil, triglycerin, trioctanoic acid, glycerine, glyceryl triisopalumitate, and the like; liquid or solid fats and oils such as coconut oil, palm oil, palm kernel oil, and the like; solid fats and oils such as cacao butter, beef tallow, mutton tallow, lard, horseflesh tallow, hydrogenated oil, hydrogenated castor oil, Japan wax, shea butter, and the like are exemplified.
- As for hydrocarbon oils, oily components such as liquid paraffin, ozokerite, squalane, squalene, pristane, paraffin, isoparaffin, ceresin, petrolatum, microcrystalline wax, and the like are exemplified.
- As for wax esters, beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, Chinese wax, spermaceti, montan wax, rice bran wax, lanolin, hydrogenated lanolin, hard lanolin, kapok wax, sugarcane wax, jojoba wax, shellac wax, and the like are exemplified.
- As for higher alcohols, cetanol, stearyl alcohol, isostearyl alcohol, 2-octyldodecanol, lanolin alcohol, and the like are exemplified.
- As for higher fatty acids, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, linolehic acid, linoleic acid, hydroxystearic acid, and the like are exemplified.
- As for ester oils, esters of octanoic acid such as cetyl octanoate and the like; esters of isooctanoic acid such as glyceryl tri(2-ethyl hexanoate), pentaerythritol tetra(2-ethylhexanoate), and the like; esters of lauric acid such as hexyl laurate, and the like; esters of myristic acid such as isopropyl myristate, 2-octyldodecyl myristate, and the like; esters of palmitic acid such as octyl palmitate, and the like; esters of stearic acid such as isocetyl stearate, and the like; esters of isostearic acid such as propyl isostearate, and the like; esters of isopalmitic acid such as octyl isopalmitate, and the like; esters of oleic acid such as isodecyl oleate, and the like; esters of adipic acid such as diisopropyl adipate, and the like; diesters of sebacic acid such as diethyl sebacate, and the like; diisostearyl malate, and the like are exemplified.
- As for polar oils, diethylene glycol monopropyl ether, polyoxyethylene polyoxypropylene pentaerythritol ether, polyoxypropylene butyl ether, ethyl linoleate, and the like are exemplified.
- As for silicones, chain silicones such as dimethyl polysiloxane, methylphenyl polysiloxane, methyl hydrogen polysiloxane, and the like; cyclic silicones such as octamethyl tetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, and the like, are exemplified.
- As for water-soluble thickening agents, vegetable type water-soluble high polymer such as arabic gum, tragacanth gum, galactene, carob bean gum, guar gum, xanthan gum, caraya gum, carrageenan, pectin, agar, quince seed (quince), algae choloid (algae extract), and the like; microbe type water-soluble high polymer such as dextran, succinoglucan, pullulan, and the like; animal type water-soluble high polymer such as collagen, casein, albumen, gelatin, and the like; cellulose type water-soluble high polymer such as methyl cellulose, nitrocellulose, ethyl cellulose, methylhydroxypropyl cellulose, hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropylcellulose, sodium carboxymethyl cellulose (CMC), microcrystalline cellulose, cellulose powder, and the like; alginic acid type water-soluble high polymer such as sodium alginate, propylene glycol alginate, and the like; vinyl type water-soluble high polymer such as polyvinyl alcohol, polyvinylmethyl ether, polyvinyl pyrrolidone, and the like; polyoxyethylene type water-soluble high polymer such as polyethylene glycol, and the like; copolymerization type water-soluble high polymer such as polyoxyethylene polyoxypropylene copolymer, and the like; acryl type water-soluble high polymer such as polyethylacrylate, polyacrylamide, and the like; Inorganic type water-soluble high polymer such as polyethyleneimine, cationic polymer, bentonite, aluminum magnesium silicate (bea gum), montmorillonite, laponite, hectorite, silicic anhydride, and the like are exemplified.
- As for lower alcohols, methanol, ethanol, propyl alcohol, isopropyl alcohol, and the like are exemplified.
- As for sterols, cholesterol, β-sitosterol, phytosterol, lanosterol, and the like are exemplified.
- As for antioxidants or assistant antioxidants, butylhydroxy toluene, tocopherol, butylhydroxyanisol, gallic acid ester, phytic acid, malic acid, and the like are exemplified.
- As for antibacterial agents, benzoic acid, salicylic acid, sorbic acid, carbolic acid, p-hydroxybenzoic acid alkyl ester (methylparaben, ethylparaben, butylparaben, and the like), benzalkonium chloride, chlorhexidine chloride, trichlorocarbanilide, photosensitizing dye, phenoxyethanol, hexachlorophene, and the like are exemplified.
- As for nonionic surfactants, sorbitan monolaurate, sorbitan sesquioleate, sorbitan tholeate, polyoxyethylene sorbitan monolaurate, polyethylene glycol monooleate, polyoxyethylene alkylether, polyglycol diester, lauroyl diethanolamide, fatty acid isopropanolamide, maltitol hydroxy fatty acid group ether, alkylated polysaccharide, alkylglucoside, sugar ester, pantothenyl ethylether, and the like are exemplified.
- As for cationic surfactants, stearyl trimethyl ammonium chloride, benzalkonium chloride, lauryl amine oxide, and the like are exemplified.
- As for anionic surfactants, sodium palmitate, sodium laurate, potassium lauryl sulfate, triethanolamine alkyl sulfate ether, turkey-red oil, linear dodecylbenzene sulfate, polyoxyethylene hydrogenated castor oil malate, acyl methyl taurate, and the like are exemplified.
- As for ultraviolet absorbers, benzoic acid type ultraviolet absorbers such as p-aminobenzoic acid, and the like; anthranilic acid type ultraviolet absorbers such as methyl anthranilate, and the like; salicylic acid type ultraviolet absorbers such as octyl salicylate, phenyl salicylate, homomenthyl salicylate, and the like; cinnamic acid type ultraviolet absorbers such as isopropyl methoxycinnamate, octyl p-methoxycinnamate, 2-ethylhexyl 4-methoxycinnamate, glyceryl octanoate di-p-methoxycimamate, 3,4,5-trimethoxycinnamate, 3-methyl-4-[methylenebis (trimethylsiloxy) silyl ] butyl, and the like; benzophenone type ultraviolet absorbers such as 2,4-dihydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, 2-hydroxy-4-methoxybenzophenone-5-sodium sulfonate, and the like; urocanic acid, ethyl urocnate, 2-phenyl-5-methylbenzoxazole, 2-(2'-hydroxy-5'-methylphenyl) benzotriazole, 4-tert-butyl-4'-methoxybenzoilmethane, and the like are exemplified.
- And, neutralizers also can be compounded to the external preparation in accordance with the present invention. For example, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1,3-propanediol, potassium hydroxide, sodium hydroxide, triethanolamine, sodium carbonate, and the like are exemplified.
- As for sequestering agents, sodium EDTA, alanine, sodium EDTA (salt), sodium polyphosphate, sodium metaphosphate, phosphoric acid, and the like are exemplified.
- As for pH adjustor, lactic acid, citric acid, glycollic acid, succinic acid, tartaric acid, dl-malic acid, potassium carbonate, sodium bicarbonate, ammonium bicarbonate, and the like are exemplified.
- As for refrigerants, menthol, penny royal oil, peppermint oil, camphor, thymol, inositol, spinlantol, methyl salicylate, and the like are preferable.
- According to the formulations which correspond to the expected formulation forms, pigments, fragrances, purified water, and the like can be compounded to the external preparation for skin in accordance with the present invention by combining properly.
- Further, proper fragrances, pigments, and the like can be added to the external preparation for skin of the present invention as occasions demand.
- In the following, the more concrete examples of the present invention will be explained. However, the present invention is not limited to these examples. And, the every expression "% by weight" as used following means "% by weight" with respect to the whole amount of the external preparation for skin.
- Firstly, the evaluation method of follow-mentioned examples will be explained.
- The measurement of the water evaporation rate has been done as the test for measuring the moisturizing effect.
- Alter dropping 10µl of sample water on 2.0cm square filter paper (TOYO Filter Paper No.2), leaving this as it is at a temperature of 25°C and relative humidity 50% the reduced weight is measured by a scale. On the assumption that the evaporation of water proceeds by linear expression, a water evaporation rate constant for each sample was found. If the weight of sample is W in time T, the rate of water is shown as,
- In integrating the above-shown formula,
-
- ⓞ : Water evaporation rate (k) is less than 0.035
- ○ : Water evaporation rate (k) is in the range from 0.035 to 0.038
- △ : Water evaporation rate (k) is in the range from 0.038 to 0.041
- X : Water evaporation rate (k) is 0.041 or more
- The water evaporation measurement constant (k) of ion- exchanged water is 0.043.
- An activator (sodium lauryl sulfate) 10% water solution was applied to some portions of the forearms of 10 males of a panel in 3 days, to intentionally make the skin rough and making skin roughness intentionally. Next, applying the following-mentioned test sample liquid was applied to the rough skin portion twice in a day and the skin surface state was measured by the replica method 5 days after starting application. The skin roughness improvement effect was evaluated by the comparison between the rough skin portion where is applied the test sample liquid and the rough skin portion where is nothing applied after the skin was roughened.
- Observing of the prepared replica by light microscope, and evaluating the symptoms of skin roughness. Namely,
- 1) occurring horny layer exfoliation and erythema,
- 2) sulci cutis and cristae are unclear, and the texture of skin is uneven, and the like has been evaluated.
-
- Remarkably effective: The symptom of skin roughness is disappeared
- Effective: The symptom of skin roughness is weakened
- Slightly effective: The symptom of skin roughness is slightly weakened
- No effect: It is not obtained any change in the symptom of skin roughness
-
- ⓞ : Where the ratio of remarkably effective, effective, and slightly effective in the examinees 80% or more
- ○ : Where the ratio of remarkably effective, effective, and slightly effective in the examinees is in the range from 50% to 80%
- △ : Where the ratio of remarkably effective, effective, and slightly effective in the examinees is in the range from 30%to 50%
- X : Where the ratio of remarkably effective, effective, and slightly effective in the examinees is less than 30%
- The skin lotion was prepared according to the formulations shown in Table 1, and the effectiveness of the external preparation for skin of the present invention was studied by doing the above-mentioned water retention test and skin roughness improvement test.
- The skin lotion was manufactured by the ordinary process.
Table 1 Test example 1 2 3 4 5 6 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 2.0 2.0 2.0 2.0 2.0 2.0 dl-α-tocopherol 0.01 - - - - - Vitamin A palmitate - 0.01 - - - - Alkyl denatured carboxyvinyl polymer - - 0.01 - - - Carboxyvinyl polymer - - - 0.01 - - Vitamin B6 - - - - 0.01 - Vitamin D - - - - - 0.01 Purified water balance balance balance balance balance balance Moisturizing effect ⓞ ⓞ ⓞ ○ △ △ Skin roughness improvement effect ⓞ ⓞ ⓞ △ ○ ○ - As is clearly from the above-mentioned Table 1, by compounding dl-α-tocopherol (vitamin E types), vitamin A palmitate (vitamin A derivatives), and alkyl denatured carboxyvinyl polymer together with trimethylglycine (quaternary ammonium salt), both the moisturizing effect and skin roughness improvement effect are excellently exhibited. However, in the case where carboxyvinyl polymer (thickening agent, humectant) is compounded, it can be observed only in the moisturizing effect practically. And in case of compounding vitamin B6 and vitamin D (vitamins which are supposed to possess the skin roughness improvement effect), it can be observed only in the skin roughness improvement effect.
- Therefore, the inventors have paid attention to the above-mentioned vitamin E types, vitamin A derivatives, and alkyl denatured carboxyvinyl polymer, and further proceeded with the study.
- Firstly, the inventors have manufactured the skin lotion which is the following Table 2 and Table 3, by the basic formulation as like Table 1. And they further studied about the mutual relation between the quaternary ammonium salt and the vitamin E types.
Table 2 Test example 1-1 1-2 1-3 1-4 1-5 1-6 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 2.0 2.0 2.0 2.0 2.0 2.0 dl-α-tocopherol 0 0.0001 0.001 0.01 0.5 2.0 Purified water balance balance balance balance balance balance Moisturizing effect △ ○ ⓞ ⓞ ⓞ ⓞ Skin roughness improvement effect △ △ ○ ⓞ ⓞ ⓞ - In test examples 1-3 to 1-6 which is compounded trimethylglycine as a quaternary ammonium salt and dl-α-tocopherol as a vitamin E types with the optimum compounding range, the skin lotion is excellent in both moisturizing effect and skin roughness improvement effect. However, when preserving the skin lotion for a long period, when a large amount of dl-α-tocopherol over test example 1-6 was compounded to the skin lotion, it sometimes caused an offensive odor. So the compounding amount of dl-α-tocopherol was preferably less than 2.0% by weight.
- Since the compounding amount of dl-α-tocopherol is relatively small, though the skin lotion of test examples 1-2 and 1-3 become slightly inconspicuous in skin roughness improvement effect as compared with the skin lotion of test examples 1-3 to 1-6. The skin lotion were worked sufficiently the expected effects of the present invention.
Table 3 Test example 1-7 1-8 1-9 1-10 1-11 1-12 1-13 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 0 0.01 0.1 8.0 10.0 20.0 30.0 dl-α-tocopherol 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Purified water balance balance balance balance balance balance balance Moisturizing effect X △ ○ ⓞ ⓞ ⓞ ⓞ Skin roughness improvement effect X △ ○ ⓞ ⓞ ⓞ ⓞ - As is clearly from Table 3, the skin lotion which is compounded 0.01% by weight or more of trimethylglycine can obtain moisturizing effect and skin roughness improvement effect, but its remarkable effect is only exhibited in the case where trimethylglycine is compounded 0.1% by weight or more to the skin lotion. In test example 1-8, the moisturizing effect can be improved by compounding other humectants additionally.
- And, in the case where trimethylglycine is compounded 30.0% by weight or more to the skin lotion, the slight powdery feeling appeared.
- From these test examples, it can be understood that the skin lotion which is compounded dl-α-tocopherol and trimethylglycine within the optimum compounding range is an excellent skin lotion which can sufficiently exhibit the expected effects.
- And, it was also proved that the skin lotion which is compounded these within the preferable compounding range can work enough for practical use in view of exhibiting the expected effect.
- Other vitamin E types except for dl-α-tocopherol which can be compounded to the external preparation for skin of the present invention is in common with dl-α -tocopherol in the fundamental pharmaceutical effects as a vitamin E types. Therefore, in case of compounding these other vitamin E types by the formulation which corresponds to the properties of each vitamin E types in place of dl-α -tocopherol, the excellent skin lotion as the test examples is provided.
- Next, the milky lotion of the formulation in Table 4 was prepared, and the effectiveness of the external preparation for skin in accordance with the present invention was studied by doing the above-mentioned water retention test and skin roughness improvement test.
Table 4 Example Comparative example 1 2 3 1 2 3 (Oil phase) Squalane 10.0 10.0 10.0 10.0 10.0 10.0 Petrolatum 2.0 2.0 2.0 2.0 2.0 2.0 Cetanol 1.0 1.0. 1.0 1.0 1.0 1.0 Lanolin alcohol 2.0 2.0 2.0 2.0 2.0 2.0 Liquid paraffin 8.0 8.0 8.0 8.0 8.0 8.0 Vitamin E acetate 0.01 0.001 0.01 - 0.01 - Antiseptic agent 0.2 0.2 0.2 0.2 0.2 0.2 Perfume 0.05 0.05 0.05 0.05 0.05 0.05 (Water phase) Carboxy vinyl polymer 0.2 0.2 0.2 0.2 0.2 0.2 Alkyl denatured carboxyvinyl polymer 0.7 0.7 0.7 0.7 0.7 0.7 KOH 0.3 0.3 0.3 0.3 0.3 0.3 Trimethylglycine 5.0 5.0 0.05 5.0 - - Purified water balance balance balance balance balance balance Moisturizing effect ⓞ ⓞ △ △ X X Skin roughness improvement effect ⓞ ○ ○ X X X - It was preemulsified by adding the heated and dissolved oil phase at 70°C to the water phase of 70°C, and further uniformly emulsified by a homomixer. After this, it was cooled down to 30°C, and the milky lotion was obtained.
- The milky lotion in accordance with the example 1 which are compounded the quaternary ammonium salt (trimethylglycine) and the vitamin E types (vitamin E acetate) within the optimum compounding range, are particular excellent in both moisturizing effect and skin roughness improvement effect.
- Since the compounding amount of vitamin E acetate is relative small as compared with example 1, the milky lotion of the example 2 become inconspicuous in skin roughness improvement effect. But, the milky lotion worked sufficiently according to the expected effect of the present invention.
- The milky lotion in accordance with the example 3 is slightly inferior in moisturizing effect. The moisturizing effect of trimethylglycine may not appear remarkably because that the compounding amount of trimethylglycine has not reached to the optimum compounding range (though the compounding amount of trimethylglycine is within the preferable compounding range). The moisturizing property can be improved by compounding other humectants to this milky lotion.
- And, all the milky lotions of these examples have not been accompanied with the powdery feel of use.
- In comparative example 1, though trimethylglycine was compounded to the external preparation for skin within the optimum compounding range, it was inferior in both moisturizing effect and skin roughness improvement effect. It is possible that the synergistic action caused by the compounding of the quaternary ammonium salt (I) and the vitamin E types is not exhibited, since the vitamin E types were not compounded at all.
- Conversely, comparative example 2 which was compounded vitamin E acetate and was not compounded with any quaternary ammonium salt (I), did not exhibit the effect of the present invention as like comparative example 1.
- And further, comparative example 3 which was not compounded with both the vitamin E types and the quaternary ammonium salt (I) (needless to say) did not exhibit the effect of the present invention.
- In these examples and comparative examples, the milky lotion which was compounded vitamin E acetate as vitamin E types and trimethylglycine as quaternary ammonium salt (I) within the optimum compounding range, sufficiently exhibited the expected effect.
- The milky lotion which was compounded vitamin E acetate (vitamin E types) and trimethylglycine (quaternary ammonium salt) within the preferable compounding range, was sufficiently fit for use, in view of the exhibition of the expected effect.
- Other vitamin E types except for vitamin E acetate which can be compounded to the already-described external preparation for skin is in common with vitamin E acetate in the fundamental pharmaceutical effects as the vitamin E types. Therefore, in case of compounding these other vitamin E types by the formulation which corresponds to the properties of each vitamin E types in place of vitamin E acetate, the excellent milky lotion as like said examples can be provided.
- Next, the inventors have manufactured the skin lotion shown in the following described Table 5 and Table 6, and the study further proceeded about the mutual relation between the quaternary ammonium salt and the vitamin A derivatives.
Table 5 Test example 2-1 2-2 2-3 2-4 2-5 2-6 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 5.0 5.0 5.0 5.0 5.0 5.0 Vitamin A palmitate 0 1×10-5 1×10-4 0.001 0.5 5.0 Purified water balance balance balance balance balance balance Moisturizing effect △ ○ ⓞ ⓞ ⓞ ⓞ Skin roughness improvement effect △ △ ○ ⓞ ⓞ ⓞ - In test examples 2-3 to 2-6 which were compounded trimethylglycine as a quaternary ammonium salt and vitamin A palmitate as a vitamin A derivatives within the optimum compounding range, the skin lotion was excellent in both moisturizing effect and skin roughness improvement effect.
- However, in preserving the skin lotion for a long period, when a large amount of vitamin A palmitate over test example 2-6 was compounded to the skin lotion, it sometimes caused an offensive odor. So the compounding amount of vitamin A palmitate is preferably 5.0% by weight or less.
- Because the skin lotion of test example 2-2 was compounded with a relative small amount of vitamin A palmitate as compared with the skin lotion of test examples 2-3 to 2-6, the skin roughness improvement effect of the skin lotion became inconspicuous. However the skin lotion was sufficiently worked the expected effect of the present invention.
Table 6 Test example 2-7 2-8 2-9 2-10 2-11 2-12 Ethanol 5.0 5.0 5.0 5.0 5.0 5.0 Polyoxyethylene oleylether (15 mol) 0.8 0.8 0.8 0.8 0.8 0.8 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 0 0.01 0.1 10.0 20.0 30.0 Vitamin A palmitate 0.001 0.001 0.001 0.001 0.001 0.001 Purified water balance balance balance balance balance balance Moisturizing effect X △ ○ ⓞ ⓞ ⓞ Skin roughness improvement effect X △ ○ ⓞ ⓞ ⓞ - As is clearly from Table 6, 0.01% by weight or more of trimethylglycine was observed moisturizing effect and skin roughness improvement effect. However, the remarkable exhibition of its effect was observed in the case where 0.1% by weight of trimethylglycine was compounded. In test example 2-8, compounding of other moisturizing ingredients improved moisturizing effect.
- And, in the case where trimethylglycine was compounded more than 30.0% by weight, a slight powdery feeling appeared.
- In these test examples, it was proved that the skin lotion which was compounded vitamin A palmitate as a vitamin A derivatives and trimethylglycine as a quaternary ammonium salt (I) within optimum compounding range was an excellent skin lotion which is sufficiently exhibited the expected effect.
- It was also proved that the skin lotion which was compounded these within the preferable compounding range was a skin lotion which was sufficiently fitted for practical use in view of the exhibition of the expected effect.
- Other vitamin A derivatives except for vitamin A palmitate which can be compounded to the described external preparation for skin of the present invention is in common with vitamin A palmitate in the basic pharmaceutical effects as a vitamin A derivatives. Therefore, in case of compounding these other vitamin A derivatives by the formulation which corresponds to the properties of each vitamin A derivative in place of vitamin A palmitate, an excellent skin lotion can be provided like the above-mentioned test examples.
- Next, milky lotion was prepared by the formulation of the following described Table 7, the effectiveness of the external preparation for skin of the present invention was studied by doing the above-described water retention test and skin roughness improvement test.
Table 7 Example 2-1 2-2 (Oil phase) Squalane 10.0 10.0 Petrolatum 2.0 2.0 Cetanol 1.0 1.0 Lanolin alcohol 2.0 2.0 Liquid paraffin 8.0 8.0 Vitamin A acetate 0.001 1×10-4 Antiseptic agent 0.2 0.2 Perfume 0.05 0.05 (Water phase) Carboxyvinyl polymer 0.2 0.2 Alkyl denatured carboxyvinyl polymer 0.7 0.7 KOH 0.3 0.3 γ-Butyroglycin 5.0 5.0 Purified water balance balance Moisturizing effect ⓞ ⓞ Skin roughness improvement effect ⓞ ○ - It was preemulsified by adding the heated and dissolved oil phase at 70°C to the water phase of 70°C, and further uniformly emulsified by a homomixer. After this, it was cooled down to 30°C, and the milky lotion was obtained.
- The milky lotion in accordance with the example 2-1 which was compounded γ-butyroglycin as a quaternary ammonium salt (I) and vitamin A acetate as a vitamin E types within the optimum compounding range was particularly excellent in both moisturizing effect and skin roughness improvement effect.
- Since the compounding amount of vitamin A acetate was relatively small as compared with example 1, the milky lotion in accordance with the example 2-2 became inconspicuous in skin roughness improvement effect. But, the milky lotion was sufficiently worked the expected effect of the present invention.
- And, all the milky lotions of these examples were not accompanied with the powdery feel of use.
- In these examples, the milky lotion which was compounded the vitamin A derivatives and the quaternary ammonium salt (I) within the optimum compounding range, can sufficiently exhibit the expected effect.
- And, the milky lotion which was compounded the vitamin A derivatives and the quaternary ammonium salt within the preferable compounding range, was sufficiently fitted for practical use in view of exhibiting the expected effect.
- Next, the inventors manufactured the composition which is described in Table 8 and Table 9, and the study further proceeded about the mutual relation between the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer.
- In case of using combined a quaternary ammonium salt and alkyl denatured carboxyvinyl polymer, if both the components are low concentrations, the composition is in a liquid state. However, if both the components are high concentrations, the composition forms a gel. This gel formative action is the phenomenon which is differentially seen by the combination of the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer. This gel formative action has been done by the following test.
- The viscosity of each samples was measured by a roater No. at 30°C by using a single cylindrical rotating viscometer (VS-A1 type) produced by Seiki Kogyo Kenkyusho (Co.,ltd.). This viscosity was evaluated as the indication of the gel formative property.
-
- ○ : Viscosity 1,500 or more (cps/30°C)
- ⓞ: Viscosity in the range from 500 to 1,500 (cps/30°C)
- △: Viscosity in the range from 100 to 500 (cps/30°C)
- X: Viscosity less than 100 (cps/30°C)
-
Table 8 Test example 3-1 3-2 3-3 3-4 3-5 3-6 Ethanol 20.0 20.0 20.0 200. 20.0 20.0 Polyoxyethylene oleyl ether (15 mol) 1.0 1.0 1.0 1.0 1.0 1.0 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 7.0 7.0 7.0 7.0 7.0 7.0 Alkyl denatured carboxyvinyl polymer 0 0.01 0.05 2.0 5.0 8..0 Purified water balance balance balance balance balance balance Moisturizing effect △ ⓞ ⓞ ⓞ ⓞ ⓞ Skin roughness improvement effect △ ⓞ ⓞ ⓞ ⓞ ⓞ Gel formative property (Viscosity) X △ ○ ⓞ ⓞ ⓞ Alkyl denatured carboxyvinyl polymer: [CARBOPOL 1342] - Polyoxyethylene oleyl ether and methylparaben were dissolved into ethanol (ethanol phase). Aside from this, the dissolution (water phase) was prepared by dissolving alkyl denatured carboxyvinyl polymer and trimethylglycine into ion-exchanged water. And then, the ethanol phase was added to the water phase and the skin lotion was obtained by solubilizing and dissolving it.
- In test examples 3-3 to 2-6 which were compounded trimethylglycine as the quaternary ammonium salt and alkyl denatured carboxyvinyl polymer within the optimum compounding range, the skin lotion was excellent in both moisturizing effect and skin roughness improvement effect. However in test example 2-6, since the skin lotion had a tendency to worsen the feel of use because the gel viscosity become too high. The amount of alkyl denatured carboxyvinyl polymer is preferably 5.0% by weight or less.
Table 9 Test example 3-7 3-8 3-9 3-10 3-11 3-12 Ethanol 20.0 20.0 20.0 20.0 20.0 20.0 Polyoxyethylene oleyl ether (15 mol) 1.0 1.0 1.0 1.0 1.0 1.0 Methylparaben 0.1 0.1 0.1 0.1 0.1 0.1 Trimethylglycine 0 0.01 0.1 5.0 20.0 30.0 Alkyl denatured carboxyvinyl polymer 0.1 0.1 0.1 0.1 0.1 0.1 Purified water balance balance balance balance balance balance Moisturizing effect X △ ○ ⓞ ⓞ ⓞ Skin roughness improvement effect X ○ ⓞ ⓞ ⓞ ⓞ Gel formative property (Viscosity) X △ △ ○ ⓞ ⓞ Alkyl denatured carboxyvinyl polymer : PEMULEN TR-2 - As is clearly from Table 9, the moisturizing effect by compounding 0.01% by weight or more of trimethylglycine can be observed, but the effect is remarkably exhibited in the case where the compounding amount of trimethylglycine is 0.1% by weight or more. In test example 3-8, moisturizing effect was improved by further compounding the other moisturizing ingredients.
- In the case where trimethylglycine is compounded 30.0% by weight or more, the slight powdery feeling was appeared.
- From the results of these test examples, it is understood that the skin lotion which was compounded alkyl denatured carboxyvinyl polymer and trimethylglycine as the quaternary ammonium salt (I) within the optimum compounding range was an excellent skin lotion which was sufficiently exhibited the expected effect.
- And, it was proved that the skin lotion which was compounded the alkyl denatured carboxyvinyl polymer and trimethylglycine (quaternary ammonium) within the preferable compounding range was sufficiently fitted for practical use in view of exhibiting the expected effect.
- Next, the milky lotion by the formulation of Table 7 was prepared, and the effectiveness of the external preparation for skin of the present invention was studied by doing the above-mentioned water retention test and skin roughness improvement test
Table 10 Example 3-1 Comparative example 3-1 3-2 Alkyl denatured carboxyvinyl polymer 0.1 0.1 0.1 γ-Butyrobetaine 5.0 - - 1,3-butylene glycol - - 5.0 Potassium hydroxide - 0.04 0.04 Purified water balance balance balance Moisturizing effect ⓞ △ ○ Skin roughness improvement effect ⓞ X △ Gel formative property (Viscosity) ○ ○ ○ Alkyl denatured carboxyvinyl polymer : [CARBOPOL 1342 ] - Example 3-1 was formed the proper viscosity gel without using the base (potassium hydroxide) as a neutralizer, and the moisturizing effect was observed to be stronger than comparative example 3-2 which was compounded a humectant.
- In the following, the compounding examples of the present invention will be explained more concretely. The external preparation for skin in accordance with the following compounding examples all show an excellent moisturizing effect and skin roughness improvement effect.
-
% by weight Oil phase Squalane 10.0 Stearic acid 2.0 Petrolatum 2.0 Cetanol 1.0 Lanolin alcohol 2.0 Liquid paraffin 8.0 dl-α-tocopherol 0.1 Antiseptic agent 0.2 Perfume 0.05 Water phase Carboxyvinyl polymer 0.2 Sodium chondroitin sulfate 1.0 Trimethylglycine 3.0 KOH 0.06 Purified water balance - After dissolving sodium chondroitin sulfate and trimethylglycine into one part of purified water, dissolving carboxyvinyl polymer and KOH into the other part of purified water. And mixing them and the water phase part is prepared After adding the above-described oil phase part which was uniformly dissolved, to the water phase part, treating it by a homomixer. Stirring and cooling it down, the expected cream was obtained.
-
% by weight Alcohol phase Polyoxyethylene alkyl ether 0.8 Menthol 0.01 Antiseptic agent 0.1 Perfume 0.1 Ethyl alcohol 20.0 Vitamin E acetate 0.02 Water phase Sodium glycyrrhizinate 0.01 Trimethylglycine 1.0 Purified water balance - After dissolving the water phase components into purified water, adding to the alcohol phase components which was dissolved into ethyl alcohol, while stirring, the expected after-shave lotion was obtained.
-
% by weight Dipropylene glycol phase Dipropylene glycol 3.0 Methyl cellulose 0.05 Antiseptic agent 0.2 d-δ-tocopherol 0.05 Water phase Carboxyvinyl polymer 0.5 Trimethylglycine 2.0 KOH 0.15 Purified water balance - After heating and dissolving an antiseptic agent to dipropylene glycol, preparing the dipropylene glycol phase by adding methyl cellulose. And, adding carboxyvinyl polymer which was dissolved in one part of purified water and trimethylglycine and KOH which was dissolved in the other part of purified water to this, the expected mask was obtained.
-
% by weight Alcohol phase POE oleyl alcohol ether 1.0 Olive oil 0.2 Antiseptic agent 0.2 Ethyl alcohol 7.0 Vitamin E acetate 0.1 Water phase Sorbitol 8.0 1,3 Butylene glycol 5.0 Polyethylene glycol 1500 7.0 Hyaluronic acid 0.1 Trimethylglycine 2.0 Purified water balance - The water phase was obtained by dissolving the above-stated water phase components to purified water. Next, POE oleyl ether, olive oil, and antiseptic agent were dissolved into ethanol successively. After heating and dissolving a soluble antiseptic agent to dipropylene glycol, and solubilizing methyl cellulose and the expected skin lotion was obtained.
-
% by weight Oil phase Squalane 10.0 Stearic acid 2.0 Petrolatum 2.0 Cethanol 1.0 Lanolin alcohol 2.0 Liquid paraffin 8.0 Vitamin A palmitate 0.01 Antiseptic agent 0.2 Perfume 0.05 Water phase Carboxyvinyl polymer 0.2 Sodium chondroitin sulfate 1.0 Trimethylglycine 5.0 KOH 0.06 Purified water balance - After dissolving sodium chondroitin sulfate and trimethylglycine into a part of purified water, and dissolving carboxyvinyl polymer and KOH into other part of purified water. Mixing them and the water phase part was prepared. After adding the above-described oil phase part which was uniformly dissolved, to the water phase part, treating it by a homomixer. Stirring it and cooling it down, the expected cream was obtained.
-
% by weight Alcohol phase Polyoxyethylene alkyl ether 0.8 Menthol 0.01 Antiseptic agent 0.1 Perfume 0.1 Ethyl alcohol 20.0 Vitamin A acetate 0.001 Water phase Sodium glycyrrhizinate 0.01 Trimethylglycine 2.0 Purified water balance - After dissolving the water phase components into purified water, and adding the alcohol phase components which were dissolved into ethyl alcohol, to the water phase while stirring, the expected after-shave lotion was obtained.
-
% by weight Dipropylene glycol phase Dipropylene glycol 3.0 Methyl cellulose 0.05 Antiseptic agent 0.2 Vitamin A palmitate 0.01 Water phase Carboxyvinyl polymer 0.5 Trimethylglycine 5.0 KOH 0.15 Purified water balance - After heating and dissolving an antiseptic agent to dipropylene glycol, preparing dipropylene glycol phase by adding methyl cellulose. And, adding carboxyvinyl polymer which was dissolved into a part of purified water and trimethylglycine and KOH which was dissolved into other part of purified water to this, the expected mask was obtained.
-
% by weight Alcohol phase POE oleyl alcohol ether 1.0 Olive oil 0.2 Antiseptic agent 0.2 Ethyl alcohol 7.0 Vitamin A palmitate 0.01 Water phase Sorbitol 8.0 1,3 Butylene glycol 5.0 Polyethylene glycol 1500 7.0 Hyaluronic acid 0.1 γ-Butyrobetaine 2.0 Purified water balance - The water phase was obtained by dissolving the above-stated water phase component to purified water. Next, POE oleyl ether, olive oil, and antiseptic agent were dissolved into ethanol successively. After heating and dissolving a soluble antiseptic agent to dipropylene glycol, and solubilizing methyl cellulose, the expected skin lotion was obtained.
-
% by weight A. Oil phase Squalane 10.0 Isopropyl palmitate 5.0 POE (25) cetyl ether 0.5 Petrolatum 3.0 Dimethyl polysiloxane 2.0 Hexyldecanol 3.0 α-tocopherol 0.3 B. Water phase Polyethylene glycol 8.0 Methyl parahydroxybenzoate 0.1 Sodium metaphosphate 0.1 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 0.5 Trimethylglycine 20.0 Ion-exchanged water balance - By Heating and dissolving phase A (oil phase) components to 70°C, heating and dissolving phase B (water phase) components to 70°C in the same way as phase A. Emulsifying by adding phase B components to phase A components while sufficiently treating by a homogenizer, and cooling it down by a heat exchanger, and the emulsion composition was obtained.
- The obtained emulsion composition had good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
-
% by weight A. Oil phase Liquid paraffin 10.0 Jojoba oil 4.0 Dimethyl polysiloxane (10cs) 3.0 POE (15) sorbitan monostearate 1.0 Glyceryl monostearate 0.5 Vitamin A oil 3.0 B. Water phase Arbutin 2.0 Magnesium ascorbyl phosphate 1.0 Placenta extract 0.5 Trisodium EDTA 0.15 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 0.15 Methylparabenzoate 0.1 Phenoxyethanol 0.2 γ-Butyrobetaine 0.1 Ion-exchanged water balance - By heating and dissolving phase A (oil phase) components to 70°C, heating and dissolving phase B (water phase) components to 70°C in the same way as phase A. Emulsifying by adding phase B components to phase A components with sufficiently treated by a homogenizer and cooling it down by a heat exchanger, the emulsion composition was obtained.
- The obtained emulsion composition had a good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
-
% by weight A. Oil phase Stearic acid 2.0 Cetyl alcohol 1.5 Petrolatum 4.0 Squalane 5.0 Glycerol tri(2-ethylhexanoate) 2.0 Sorbitan monooleate 2.0 2-ethylhexyl 4-methoxycinnamate 2.0 dl-tocopheryl acetate 0.5 Ethyl parahydroxybenzoate 0.1 B. Water phase Dipropylene glycol 5.0 Polyethylene glycol (1500) 0.15 Trisodium EDTA 5.0 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 5.0 Carboxy methyl cellulose 0.8 Trimethylglycine 10.0 Potassium hydroxide 1.0 Ion-exchanged water balance - Using a part of ion-exchanged water of phase B, and the gel was formed by dissolving [CARBOPOL 1342] and trimethylglycine into this. By heating and dissolving Phase A (oil phase) components to 70°C, heating and dissolving Phase B (water phase; except for [CARBOPOL 1342] and trimethylglycine) components to 70 °C in the same way as phase A components. Emulsifying by adding phase B components to phase A components while sufficiently treating by a homogenizer and cooling it down by a heat exchanger, the emulsion composition was obtained.
- The obtained emulsion composition had a good gel formative property (viscosity), and was excellent in moisturizing property and skin roughness improvement effect.
-
% by weight Sorbitol 4.0 Dipropylene glycol 6.0 Polyethylene glycol 5.0 Ethanol 10.0 POE (20) oleyl alcohol ether 0.5 Alkyl denatured carboxyvinyl polymer ([CARBOPOL 1342]) 0.15 γ-Butyrobetaine 0.8 Ion-exchanged water balance - Using a part of ion-exchanged water, and the gel was obtained by dissolving [CARBOPOL 1342] and trimethylglycine into this. By adding sorbitol, dipropylene glycol, and polyethylene glycol (1500) after heating to 70°C to the balance of ion-exchange water. And then, by adding the above-mentioned gel to this, an uniform water solution was obtained. After preparing an alcohol solution by adding POE (20) oleyl alcohol to ethanol, the solubilized composition was obtained by adding this alcohol solution to the above-mentioned uniform water solution.
- The obtained solubilizing composition had a good gel formative property (viscosity) and excellent moisturizing property, and also had a skin roughness improvement effect.
Claims (11)
- An external preparation for skin comprising: a quaternary ammonium salt which is shown by following constitutional formula (I), an enhancer of moisturizing effect, and skin roughness improvement effect of a quaternary ammonium salt selected from the group consisting of vitamin E types, vitamin A derivatives, and alkyl denatured carboxyvinyl polymer;
- An external preparation according to claim 1, wherein the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 30% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 1, wherein the compounding amount of the quaternary ammonium salt is in the range from 0.1% by weight to 20% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 1, wherein vitamin E types are tocopherol and/or vitamin E acetate.
- An external preparation according to claim 4, wherein the compounding amount of the vitamin E types is in the range from 0.0001% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 4, wherein the compounding amount of the vitamin E types is in the range from 0.001% by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 1, wherein vitamin A derivatives are vitamin A ester.
- An external preparation according to claim 7, wherein the compounding amount of the vitamin A derivatives is in the range from 1 × 10-5% by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 7, wherein the compounding amount of the vitamin A derivatives is in the range from1 × 10-4% by weight to 0.5% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 1, wherein the compounding amount of alkyl denatured carboxyvinyl polymer is in the range from 0.01% by weight to 5.0% by weight with respect to the whole amount of the external preparation.
- An external preparation according to claim 1, wherein the compounding amount of alkyl denatured carboxyvinyl polymer is in the range from 0.05% by weight to 2.0% by weight with respect to the whole amount of the external preparation.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19910395 | 1995-07-12 | ||
JP19910395 | 1995-07-12 | ||
JP199103/95 | 1995-07-12 | ||
JP27683195 | 1995-09-29 | ||
JP27683195 | 1995-09-29 | ||
JP276831/95 | 1995-09-29 | ||
JP276345/95 | 1995-09-30 | ||
JP27634595 | 1995-09-30 | ||
JP27634595 | 1995-09-30 | ||
PCT/JP1996/001940 WO1997002803A1 (en) | 1995-07-12 | 1996-07-12 | External skin preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0780116A1 true EP0780116A1 (en) | 1997-06-25 |
EP0780116A4 EP0780116A4 (en) | 1997-09-10 |
EP0780116B1 EP0780116B1 (en) | 2002-09-25 |
Family
ID=27327598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96923068A Revoked EP0780116B1 (en) | 1995-07-12 | 1996-07-12 | External skin preparation |
Country Status (7)
Country | Link |
---|---|
US (1) | US6008246A (en) |
EP (1) | EP0780116B1 (en) |
JP (1) | JP3609834B2 (en) |
KR (1) | KR100423458B1 (en) |
DE (1) | DE69623914T2 (en) |
TW (1) | TW448053B (en) |
WO (1) | WO1997002803A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000158A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing quaternary ammonium compounds |
WO2001000165A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing a quaternary ammonium compound and tocopherol |
WO2001000164A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing vitamin b3 |
US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
EP1417956A2 (en) * | 2002-11-07 | 2004-05-12 | The Procter & Gamble Company | Film-forming compositions for topical application |
WO2004073678A1 (en) * | 2003-02-18 | 2004-09-02 | The Procter & Gamble Company | Film-forming compositions for topical application |
EP1561457A3 (en) * | 2004-02-03 | 2006-01-18 | Alberto-Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19711452A1 (en) * | 1997-03-19 | 1998-09-24 | Sca Hygiene Paper Gmbh | Moisture regulator-containing composition for tissue products, process for the production of these products, use of the composition for the treatment of tissue products and tissue products in the form of wetlaid, including TAD or airlaid (non-woven) based on flat carrier materials predominantly containing cellulose fibers |
AUPO690997A0 (en) * | 1997-05-20 | 1997-06-12 | Novapharm Research (Australia) Pty Ltd | Alkylpolyglucosides containing disinfectant compositions active against pseudomonas microorganism |
SG71877A1 (en) | 1997-12-19 | 2000-04-18 | Johnson & Johnson Consumer | Novel powder compositions |
US20040067212A1 (en) * | 1998-03-11 | 2004-04-08 | Kabushiki Kaisha Soken | Skin conditioner |
EP0988854B1 (en) | 1998-09-21 | 2004-07-14 | Shiseido Company Limited | Composition for external use containing succinoglucan, clay mineral and an alkyl acrylate/methacrylate copolymer |
US7083781B2 (en) * | 1999-08-19 | 2006-08-01 | Lavipharm S.A. | Film forming polymers, methods of use, and devices and applications thereof |
US20030087789A1 (en) * | 2000-03-28 | 2003-05-08 | Scheffler Armin | Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
JP4612180B2 (en) * | 2000-12-19 | 2011-01-12 | 株式会社ヤクルト本社 | Skin preparation |
US6893631B1 (en) | 2001-06-14 | 2005-05-17 | Mitchell & Sons, Llc | Shaving soap and aftershave gel and methods of use thereof |
CN1547475B (en) * | 2001-07-27 | 2010-12-15 | 生命健康科学有限公司 | Dermal therapy using phosphate derivatives of electron transfer agents |
DE10148966A1 (en) * | 2001-10-04 | 2003-04-10 | Beiersdorf Ag | Betaines are used in improving the sensory properties and foreign matter (especially sand) repellency of polyol-containing cosmetic or dermatological compositions |
US7416756B2 (en) | 2003-09-10 | 2008-08-26 | Eastman Chemical Company | Process for the recovery of a phytolipid composition |
EP2275078B1 (en) * | 2004-08-13 | 2016-12-07 | Henkel AG & Co. KGaA | Cosmetic and dermatological compositions comprising (2-hydroxyethyl)urea |
KR20080019228A (en) | 2005-06-17 | 2008-03-03 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Carrier containing at least one di and / or mono- (electrotransfer) phosphate derivative or complex salt thereof |
US20070110780A1 (en) * | 2005-11-14 | 2007-05-17 | Nzymsys, Ip Inc. | Building material surface treatment biocide, and method for treatment of building material surfaces |
US20070218143A1 (en) * | 2006-03-20 | 2007-09-20 | Chong Mok T M | Topical preparation |
US20070280919A1 (en) * | 2006-05-30 | 2007-12-06 | Gorton Stephen J | Produce-treatment composition and method for treatment of fresh produce |
MY153862A (en) * | 2007-11-28 | 2015-03-31 | Colgate Palmolive Co | Alpha or beta hydroxy acid adducts of oil |
JP4726151B2 (en) * | 2008-10-15 | 2011-07-20 | 株式会社 資生堂 | Skin preparation for external use |
ES2999020T3 (en) | 2010-02-05 | 2025-02-24 | Phosphagenics Ltd | Carrier comprising non-neutralised tocopheryl phosphate |
TWI507193B (en) | 2010-03-30 | 2015-11-11 | Phosphagenics Ltd | Transdermal delivery patch |
JP5827052B2 (en) * | 2010-07-16 | 2015-12-02 | ロート製薬株式会社 | Composition for external use |
EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | Amino-quinolines as kinase inhibitors |
JP6882321B2 (en) | 2015-12-09 | 2021-06-02 | フォスファージニクス リミテッド | Pharmaceutical product |
CA3045702A1 (en) | 2016-12-21 | 2018-06-28 | Phosphagenics Limited | Phosphorylation process of complex alcohols |
CA3081624A1 (en) | 2018-01-04 | 2019-07-11 | Amryt Research Limited | Betulin-containing birch bark extracts and their formulation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203750A2 (en) * | 1985-05-13 | 1986-12-03 | The Procter & Gamble Company | Ultra mild skin cleansing composition |
WO1992019216A1 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble Company | Skin and hair-care gel compositions |
WO1992019218A2 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble Company | Cosmetic compositions |
WO1992019275A2 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble_Company | Cosmetic compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS522979B2 (en) * | 1972-09-29 | 1977-01-25 | ||
US4490355A (en) * | 1983-03-14 | 1984-12-25 | Miranol Chemical Company, Inc. | Betaine based cosmetic formulations |
US4954332A (en) * | 1987-10-22 | 1990-09-04 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
FR2662605B1 (en) * | 1990-05-31 | 1994-12-02 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HAIR AND SCALP. |
JP3035742B2 (en) * | 1990-11-30 | 2000-04-24 | 昭和電工株式会社 | Cosmetics |
EP0570230B1 (en) * | 1992-05-15 | 1998-09-30 | Shiseido Company Limited | External preparation for skin |
JPH06293625A (en) * | 1993-04-08 | 1994-10-21 | Asahi Chem Ind Co Ltd | Toilet lotion |
-
1996
- 1996-07-12 DE DE69623914T patent/DE69623914T2/en not_active Revoked
- 1996-07-12 KR KR1019970701617A patent/KR100423458B1/en not_active IP Right Cessation
- 1996-07-12 US US08/793,864 patent/US6008246A/en not_active Expired - Lifetime
- 1996-07-12 WO PCT/JP1996/001940 patent/WO1997002803A1/en not_active Application Discontinuation
- 1996-07-12 JP JP50568497A patent/JP3609834B2/en not_active Expired - Lifetime
- 1996-07-12 EP EP96923068A patent/EP0780116B1/en not_active Revoked
- 1996-08-19 TW TW085110114A patent/TW448053B/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203750A2 (en) * | 1985-05-13 | 1986-12-03 | The Procter & Gamble Company | Ultra mild skin cleansing composition |
WO1992019216A1 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble Company | Skin and hair-care gel compositions |
WO1992019218A2 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble Company | Cosmetic compositions |
WO1992019275A2 (en) * | 1991-05-04 | 1992-11-12 | The Procter & Gamble_Company | Cosmetic compositions |
Non-Patent Citations (1)
Title |
---|
See also references of WO9702803A1 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000158A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing quaternary ammonium compounds |
WO2001000165A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing a quaternary ammonium compound and tocopherol |
WO2001000164A1 (en) * | 1999-06-28 | 2001-01-04 | The Procter & Gamble Company | Cosmetic compositions containing vitamin b3 |
EP1417956A2 (en) * | 2002-11-07 | 2004-05-12 | The Procter & Gamble Company | Film-forming compositions for topical application |
EP1417956A3 (en) * | 2002-11-07 | 2004-08-11 | The Procter & Gamble Company | Film-forming compositions for topical application |
US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
WO2004073678A1 (en) * | 2003-02-18 | 2004-09-02 | The Procter & Gamble Company | Film-forming compositions for topical application |
EP1561457A3 (en) * | 2004-02-03 | 2006-01-18 | Alberto-Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
US7691399B2 (en) | 2004-02-03 | 2010-04-06 | Alberto Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
EP2281549A1 (en) * | 2004-02-03 | 2011-02-09 | Alberto-Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
Also Published As
Publication number | Publication date |
---|---|
KR100423458B1 (en) | 2004-05-17 |
US6008246A (en) | 1999-12-28 |
KR970705973A (en) | 1997-11-03 |
TW448053B (en) | 2001-08-01 |
WO1997002803A1 (en) | 1997-01-30 |
EP0780116B1 (en) | 2002-09-25 |
EP0780116A4 (en) | 1997-09-10 |
JP3609834B2 (en) | 2005-01-12 |
DE69623914T2 (en) | 2003-05-15 |
DE69623914D1 (en) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6008246A (en) | External preparation for skin containing a low-molecular-weight betaine | |
US5641495A (en) | Skin cosmetic containing ceramides of pseudoceramides and dicarboxylic acids and dicarboxylic acid salts | |
JP3483988B2 (en) | Skin preparation | |
EP0763354B1 (en) | Oil/water mixture composition | |
JP2937446B2 (en) | Blackening agent to prevent gray hair | |
US5753242A (en) | External skin treatment composition | |
JP2009263346A (en) | Emulsion-type cosmetic containing kinetin | |
JPH11130652A (en) | Skin cosmetic | |
JPH09315937A (en) | Gelled composition, emulsion composition and preparation for external use for skin | |
JP2983311B2 (en) | External preparation for skin | |
JPH0995432A (en) | Preparation for external use for skin | |
JP2004131401A (en) | Skin cosmetic | |
JP3447177B2 (en) | Gel composition | |
JPH0687730A (en) | Cosmetic | |
JPH07215839A (en) | Skin external agent | |
JPH0995411A (en) | Preparation for external use for skin | |
JP3091267B2 (en) | Emulsified cosmetic | |
JP2000256167A (en) | Skin lotion | |
JPH08268866A (en) | Dermal preparation for external use | |
JP4275872B2 (en) | Mixing topical skin composition for use | |
JPH115725A (en) | Preparation for external use for skin | |
JPH1095706A (en) | Emulsifying agent composition | |
JPH07215832A (en) | Skin external preparation | |
JPH09124437A (en) | Emulsified composition and dermal preparation for external use | |
JPH10273413A (en) | Skin preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE ES FR GB IT NL |
|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): DE ES FR GB IT NL |
|
17P | Request for examination filed |
Effective date: 19970725 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SHISEIDO COMPANY LIMITED |
|
17Q | First examination report despatched |
Effective date: 20000919 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT NL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020925 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69623914 Country of ref document: DE Date of ref document: 20021031 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030328 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
26 | Opposition filed |
Opponent name: RIGANO, LUIGI DR. Effective date: 20030625 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040706 Year of fee payment: 9 |
|
RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20050704 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050712 Year of fee payment: 10 |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
27W | Patent revoked |
Effective date: 20050222 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Free format text: 20050222 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060731 Year of fee payment: 11 |